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ABSTRACT 
 RNA-Seq (Whole Transcriptome Shotgun Sequencing) provides an ideal platform 
to study the complete set of transcripts for a specific developmental stage or 
physiological condition.  It reveals not only expression-level changes, but also structural 
changes in the coding sequences, including gene rearrangements.  In this dissertation, I 
present my contributions to the development of computational tools for the robust and 
efficient analysis of RNA-Seq data to support cancer research.  
To automate the laborious and computationally intensive procedure of RNA-Seq 
data management, I worked on the development of Hydra, an RNA-Seq pipeline for the 
parallel processing and quality control of large numbers of samples.  With user-friendly 
reports on quality control and running checkpoints, Hydra makes the data processing 
procedure fast, efficient and reliable.  Here, I report my application of the pipeline to the 
analysis of patient-derived lymphoma xenograft samples, to show Hydra’s ability to 
detect abnormalities (e.g., mouse tissue contamination) in the sequencing data.  
  vi 
Because fusions play an important role in carcinogenesis, fusion detection has 
become an important area of methodological research.  Several computational methods 
have been developed to identify fusion transcripts from RNA-Seq data.  However, all 
these methods require realignment to the transcriptome, a computationally expensive task, 
unnecessary in many cases.  Here, I present QueryFuse, a novel gene-specific fusion-
detection algorithm for aligned RNA-Seq data.  It is designed to help biologists find 
and/or computationally validate fusions of interest quickly, and to annotate the detected 
events with visualization and detailed properties of the supporting reads.  By focusing the 
fusion detection on read pairs aligned to query genes, we can not only reduce realignment 
time, but also afford to use a more accurate but computationally expensive local aligner.  
In the extensive evaluation I performed, I obtained comparable or better results compared 
with two widely adopted tools (deFuse and TophatFusion) on two simulated datasets, as 
well as on cell line datasets with known fusions.  Finally, I contributed to the 
identification of a novel fusion event in lymphoma, with potential therapeutic 
implications in clinical samples.   I validated this fusion in silico by my putative reference 
method before experimental validation. 
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Terms Definition 
Both-end-unmapped 
(BEU) 
Reads where both paired-ends are unmapped. 
Fragment A contiguous sequence of nucleotides from a cDNA molecule. 
Fusion boundaries The precise, nucleotide-level genomic coordinates of the 
breakpoints on both sides of the fusion gene pair. 
High similarity 
region 
A >30-bp-long sequence that occurs multiple times across the 
genome. 
Insert region The non-sequenced fragment portion between paired ends. 
Insert-size The size of an insert region 
Paired-end-aligned 
(PEA) 
Reads in which both members of the pair are properly aligned 
to the reference. 
Paired ends Two sequenced ends in the paired-end sequencing. 
Paired-end 
sequencing 
The protocol of sequencing both ends of the same fragment. 
PREF An in silico fusion validation tool for RNA-Seq data. 
QueryFuse A gene-specific fusion-detection algorithm for RNA-Seq data. 
Read A sequenced end of a fragment. 
Shifted region A region in which shifting the breakpoint location will not 
change the fusion sequence. 
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SimFuse An RNA-Seq based fusion simulator. 
Single-end-aligned 
(SEA) 
Read pairs where only one of the ends is properly aligned. 
Spanning reads PEA reads that have the fusion boundaries in the insert region. 
Splitting read A read with the fusion boundaries within its length. 
Unmapped Not properly aligned. 
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CHAPTER 1: INTRODUCTION 
 “Cancer is a major cause of morbidity and mortality, with approximately 14 
million new cases and 8 million cancer-related deaths in 2012, affecting populations in all 
countries and all regions” (Stewart & Wild 2014). A comprehensive understanding of the 
mechanisms of cancer initiation and progression is crucial for cancer diagnosis, 
prevention and cure. High-throughput technologies, especially deep-sequencing 
technologies, give researchers powerful tools to study cancer. 
Deep-sequencing technologies report genomic information at base pair (bp) 
resolution level. They are now widely used for genome assembly, structural variation 
detection (mutation, translocation, etc.), gene expression profiling, etc.  
As a fast developing technology, the cost of deep-sequencing decreased more than 
ten thousand times in the past 15 years, a rate of improvement exceeding Moore’s law 
(Wetterstrand n.d.). Although the cost per base pair is minimal, performing whole 
genome sequencing (WGS) is still too expensive to be widely used in clinical research. 
On the other hand, because whole-transcriptome sequencing (RNA-Seq) can reveal the 
dynamic changes of RNAs (Chu & Corey 2012) and can provide much greater depth of 
coverage (>50 times) than WGS for the same total number of sequencing reads (Ensembl 
n.d.), it has become a widely adopted assay in clinical research.  The consequent 
pervasive adoption of RNA-sequencing in cancer research is the main impetus behind the 
development of computational tools for the analysis of the ever-increasing volume of 
RNA-Seq data.   
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There are a few dominantly standard tools for the primary data analysis. For 
example, FastqQC (Andrews n.d.) for quality control; blat (Kent 2002) and blast 
(Altschul et al. 1990) for local alignment; bowtie (Langmead et al. 2009) and BWA (Li & 
Durbin 2009) for global alignment; Tophat (Trapnell et al. 2009) and STAR (Dobin et al. 
2013) for RNA splice alignment. For each downstream, specified analysis (such as 
expression profiling, structure variation detection, etc.), there are various alternatives to 
fit different scenarios and hypotheses. While tools for each single step of the analysis are 
available, the full analysis process (the ‘pipeline’ from raw reads to downstream results) 
is still difficult and requires considerable computational infrastructure and sophistication.  
In this work, I investigate computational approaches for the analysis of whole-
transcriptome RNA-Seq data for cancer research, with a focus on data pre-processing and 
quality control (QC), and gene fusion detection. The goal is to develop a generalized 
RNA-Seq QC and data processing pipeline to facilitate data analysis, and a well-validated 
fusion-detection tool based on a novel algorithm that I designed and implemented. 
Section 1.1: Overview of the Biological and Computational Motivations 
 I chose to focus on cancer because it is a life-threatening and pervasive disease, 
responsible for 589,430 deaths in the U.S. in 2015 (Rl et al. 2015), and gene fusions play 
an important role in driving tumorigenesis (Section 1.1.1).  In section 1.1.2, I compare 
DNA sequencing with RNA sequencing and explain why I use RNA-Seq data as my 
main data type. Section 1.1.3 gives a brief overview of existing RNA-Seq based fusion-
detection tools and of their shortcomings that my algorithm (QueryFuse) aims to address. 
Section 1.1.4 shows how to evaluate the performance of RNA-Seq based fusion-detection 
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tools, and explains what potential contributions a statistically powerful fusion simulator 
(SimFuse) and an in silico fusion validation tool (PREF) can have. 
Section 1.1.1: Cancer and Gene Fusions 
Although the U.S. alone spent over $200 billion on cancer research from 1971 to 
2005 (Begley 2008) and the death rate for cancer (adjusted for the size and age) had 
dropped 5% from 1950 to 2005 (Kolata 2009), cancer remains one of the public health 
battles in which we have made little progress. 
One of the main progress is the discover of the essence of cancer is  a genetic 
disease (Vogelstein & Kinzler 2004) and two dominant types of initiating genetic events 
(Mitelman et al. 2007) and ten hallmarks of cancer have been proposed (Hanahan & 
Weinberg 2000; Hanahan & Weinberg 2011). These genetic events and hallmarks include 
DNA deletions, insertions, mutations, translocations, etc. Among them, translocations 
and their corresponding gene fusions have an important role in the initial steps of 
carcinogenesis (Mitelman et al. 2007).  
 A gene fusion, also referred to as chromosomal translocation, denotes the event 
whereby two normally separated genes are joined together as a consequence of DNA 
double strand breaks (DSBs) followed by a DNA repair error (Mitelman et al. 2007; 
Aplan 2006). A special type of normal gene fusion called V(D)J recombination is the 
main process by which the human immune system generates new antibodies (Malu et al. 
2012). However, gene fusions are also known to play important roles in tumor initiation 
and progression in nearly all tumor types (Vega & Medeiros 2003; Mitelman et al. 2007). 
It has been shown that, on the one hand, the decrease or eradication of a disease-
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associated chimera can be a successful treatment, while on the other hand, manipulated 
gene fusions can give rise to neoplastic disorders (Mitelman et al. 2007). 
Similar to mutations, gene fusions can change the fusion genes’ reading frame, 
stop codon, protein sequence and structure, or replace regulation elements. These events 
lead to the formation of new chimeric proteins or dysregulation of the fusion gene’s 
expression (Mitelman et al. 2007; McPherson et al. 2011).  BCR-ABL1 is a classic 
example of a chimeric protein in chronic myelogenous leukemia (CML). Its protein 
product induces inhibition of apoptosis, growth factor independence and leukemogenesis 
(McPherson et al. 2011; Fernandez-Luna 2000). The drug Imatinib can shut down BCR-
ABL1 enzymatic activity and stop cancer cell growth, resulting in significant 
improvement of the 5-year survival rate (increased from 30% to 89%) for CML patients 
(Goldman & Melo 2003; Kantarjian et al. 2012). Another example of tumor-driving gene 
rearrangement is the fusion of the ETS and TMPRSS2 genes, which lead to expression 
dysregulation in prostate cancer (McPherson et al. 2011; Yu et al. 2010). 
Because gene fusions involve a DNA DSB and mis-repair (Mitelman et al. 2007; 
McPherson et al. 2011; Aplan 2006), whole genome sequencing (WGS) with deep 
coverage is the ideal approach to find all gene fusions in a sample.  
Section 1.1.2: DNA Sequencing (DNA-Seq) vs. RNA Sequencing (RNA-Seq) 
DNA-Seq is the high-throughput process of determining the precise nucleotide 
composition of DNA molecules in a library by a sequencer. Traditionally, DNA-Seq 
refers to whole genome sequencing, which uses the complete DNA of an organism’s 
genome as the sequencing library. Depending on the library preparation method, DNA-
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Seq can also be used for whole exon sequencing (WES), which focuses only on the exon 
regions, and targeted sequencing, which focuses only on the targeted regions. Because 
the number of targets are different among these methods (WGS > WES > targeted 
sequencing), with the same sequencing power, the sequencing depth of these three 
methods are in the opposite direction (targeted sequencing > WES > WGS). DNA-Seq 
methods are widely used in finding genetic variation, genomic mutations and structural 
change, etc.  
While DNA-Seq targets DNA molecules, RNA-Seq targets RNA by building a 
cDNA library using reverse transcription. Similar to WGS targeting the whole genome, 
RNA-Seq targets only the transcriptome present at a given moment (Chu & Corey 2012). 
Because only a small portion of the genome is transcribed to be functional at any given 
time, with the same number of sequencing reads RNA-Seq can provide much higher 
depth (>50 times) than WGS (Ensembl n.d.), which makes RNA-Seq cost effective and 
much more sensitive than WGS on detecting low-frequency variations. Additionally, 
RNA-Seq has the advantage of targeting transcribed functioning transcripts, which make 
it an ideal platform to detect clinical actionable targets. Therefore, in this dissertation, I 
focus on developing computational tools for RNA-Seq data analysis to support cancer 
research. 
The task of processing and QC-ing RNA-seq data is laborious and 
computationally intensive, and comprehensive tools for the “bench-to-bedside” 
processing of RNA-Seq data – including raw data quality check, sequence alignment, 
alignment quality check, expression quantification, etc. – are still lacking. Therefore, I 
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contributed to the development of Hydra, an RNA-Seq pipeline for parallel processing 
and quality control of large numbers of samples. 
Section 1.1.3: RNA-Seq Based Fusion-Detection Tools 
 In the past five years, at least 18 RNA-Seq based fusion-detection tools have been 
published (Table 1.1). This shows that fusion detection from RNA-Seq data is receiving 
more and more attention. Generally, RNA-Seq based fusion-detection tools can be 
categorized into two groups: 1) fragment based approaches, and 2) pseudo-reference 
based approaches (Table 1.1). Fragment based approaches split reads into fragments and 
align fragments to a regular reference genome/transcriptome. Pseudo-reference based 
approaches generate pseudo-reference by de novo assembling and use it together with the 
regular reference (Carrara, Beccuti, Cavallo, et al. 2013). Although most of the RNA-Seq 
based fusion-detection tools are designed specifically for fusion detection, some are 
RNA-Seq aligners with integrated fusion-detection models (Table 1.1). 
Name 
Publication 
Date 
Approach 
Aligner with 
Integrated Fusion 
Detection Module 
BreakFusion (Chen et al. 
2012) 
Jul 2012 
Pseudo-reference 
based 
No 
defuse (McPherson et al. 
2011) 
May2011 Fragment based No 
EricScript (Benelli et al. 
2012) 
Oct 2012 
Pseudo-reference 
based 
No 
FusionFinder (Francis et 
al. 2012) 
Jun 2012 Fragment based No 
FusionHunter (Li et al. 
2011) 
Apr 2011 
Pseudo-reference 
based 
No 
FusionMap (Ge et al. 
2011) 
Jul 2011 Fragment based No 
FusionQ (Liu et al. 2013) Jun 2013 
Pseudo-reference 
based 
No 
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FusionSeq (Sboner et al. 
2010) 
Oct 2010 
Pseudo-reference 
based 
No 
STAR (Dobin et al. 
2013) 
Oct 2012 
Pseudo-reference 
based 
Yes 
SOAPfuse (Jia et al. 
2013) 
Feb 2013 Fragment based Yes 
TophatFusion (Kim & 
Salzberg 2011) 
Aug 2011 
Pseudo-reference 
based 
Yes 
TransABySS (Robertson 
et al. 2010) 
Oct 2010 
Pseudo-reference 
based 
Yes 
Bellerophontes (Abate et 
al. 2012) 
Aug 2012 
Pseudo-reference 
based 
No 
ChimeraScan (Iyer et al. 
2011) 
Aug 2011 
Pseudo-reference 
based 
No 
mapSplice (Wang et al. 
2010) 
Oct 2010 Fragment based Yes 
SnowShoes-FTD 
(Asmann et al. 2011) 
Apr 2011 Fragment based No 
ShortFuse (Kinsella et al. 
2011) 
Feb 2011 Fragment based No 
FusionCatcher (Nicorici 
et al. 2014) 
Nov 2014 Fragment based No 
Table 1.1: RNA-Seq based fusion-detection tools.  
Existing RNA-Seq based fusion-detection algorithms have two common features: 
1) they use raw reads as input (except Breakfusion); 2) they perform global fusion 
detection.  
Regardless of the downstream analysis that will be performed (e.g., structure 
variation analysis, expression quantification analysis), alignment is consistently the first 
step of all RNA-Seq analyses because it generates usable transcriptomic information 
from RNA-Seq data. Although using raw reads as input can minimize the bias from the 
aligner, aligning these raw reads is the most time consuming, inefficient and unnecessary 
step in most fusion detection cases. In a regular RNA-Seq library, more than 90% of the 
reads are not fusion related. Because of this, aligning all the reads again in the fusion 
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detector is inefficient. This means that fusion-detection tools could more efficiently use 
already aligned data instead of raw data.  
Although for high-throughput data, global detection can reveal the big picture, for 
lots of researchers, especially for biologists, a long list of all potential fusion events is 
overwhelming. This is because they often care about only a limited list of genes. 
Therefore, a fusion-detection tool that focuses on only a select list of genes is needed. 
Section 1.1.4: Performance Estimation of RNA-Seq Based Fusion-Detection Tools 
Although many RNA-Seq based fusion-detections tools were developed, there is 
no gold standard to evaluate the performance of these algorithms. Most of the listed 
fusion-detection tools were tested only on real data (cell lines or patient samples) with 
RT-PCR validations of a limited number of predicted fusions, which precluded the 
accurate estimation of recall and precision (Powers 2011). Therefore, real data are useful 
to test whether a method is successful in detecting specific events, but are not sufficient 
to comprehensively estimate the method’s predictive performance. A statistically 
powerful simulated dataset containing large numbers of known true positives and true 
negatives is the complementary solution. 
Some of the published fusion-detection tools (Carrara, Beccuti, Cavallo, et al. 
2013; Carrara, Beccuti, Lazzarato, et al. 2013; Jia et al. 2013) utilized an RNA-Seq based 
simulated fusion dataset generated as part of the evaluation of FusionMap (Ge et al. 
2011). However, this is a small dataset representing a single sample and a total of 50 
fusions. A fusion simulator able to automatically generate multiple datasets with various 
numbers and types of fusion supporting reads could facilitate the performance evaluation 
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of new and existing fusion-detection algorithms. In this work, I propose SimFuse, a novel 
fusion simulator, to address this gap. 
Although the gold standard to validate a fusion event is by a set of experiments, 
these experiments are resource intensive and time-consuming and thus most detected 
fusions were not experimentally validated. By generating a putative sequence of a fusion 
as the reference, supporting reads can be thoroughly extracted from RNA-Seq data. 
Therefore, this method can serve as a computational validation and exclude fusions with 
a low supporting level. Here, I propose PREF, a novel tool to in silico validate 
hypothesized or detected fusion from RNA-Seq data. 
Section 1.2: Summary 
RNA-Seq provides a cost-effective approach to detect clinical actionable targets, 
which makes it an ideal platform for cancer research. To automatize the laborious and 
computationally intensive procedure of analyzing RNA-Seq data, Hydra, an RNA-Seq 
pipeline, was developed for parallel processing and quality control of large numbers of 
samples. 
Gene fusions play important roles in tumorigenesis and progression, and serve as 
targets of targeted drugs that have considerable clinical success. These facts have lead 
RNA-Seq based fusion detection to become a popular area of methodological research, 
and more than 18 computational tools have been developed to globally identify fusion 
transcripts from RNA-Seq data. However, all these tools require realignment which is 
computationally expensive and, in many cases, unnecessary. Additionally, instead of 
global detection, gene-specific detection can reduce runtime and perform accurately. 
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Hence, I propose QueryFuse, a novel gene-specific fusion-detection algorithm for aligned 
RNA-Seq data. 
Real data is not sufficient to comprehensively estimate the method’s predictive 
performance, and a statistically powerful simulated dataset containing large numbers of 
known true positives and true negatives is the complementary solution. Here, I present 
SimFuse, a novel fusion simulator, to facilitate performance estimation of fusion-
detection algorithms.  
As a complementary solution for the laborious, time-consuming fusion validation 
experiments, I propose PREF, an in silico fusion validation tool, to computationally 
validate fusions before moving onto experiments. 
Section 1.3: Guide for the Reader 
In Chapter 2, I review in detail the relevant concepts and methods necessary for 
the presentation of tools I developed. First, I introduce the regular workflow of RNA-Seq 
data processing and related tools. Second, I introduce the commonly used seed method in 
fusion detection, and I compare it with my own new split-searching algorithm. Third, I 
briefly summarize existing RNA-Seq based fusion simulation datasets and the challenges 
of simulating fusions from RNA-Seq data. Finally, I describe concepts that enable in 
silico validation of detected fusions. 
In Chapter 3, I detail the methodologies of our proposed tools. First, I describe 
Hydra, an RNA-Seq pipeline to facilitate data processing, which provides input data for 
downstream fusion detection. Second, I outline QueryFuse, a gene-specific fusion-
detection algorithm, which is the key contribution in my dissertation. Third, I present 
  
11 
SimFuse, an RNA-Seq based fusion simulator, to estimate performance of QueryFuse 
and two other state-of-the-art fusion-detection algorithms. Finally, I illustrate PREF, an in 
silico fusion validation tool to validate fusions detected in our in-house cancer research. 
In Chapter 4, I present all datasets used in this dissertation. All these datasets 
were run through Hydra for data processing, and then used in the research of fusion 
detection. Simulation datasets with known true positives and true negatives were used to 
get recall and precision rate of fusion-detection algorithms. Cell line datasets with 
experimentally validated fusion were used to estimate the likelihood of detecting a true 
positive fusion in the real data. The patient datasets are from our cancer research projects, 
in which I applied my own algorithms as well as existing tools to find cancer markers 
(differential expression and gene fusion). 
In Chapter 5, I show the results and discussions of proposed tools. First, I use an 
application example of Hydra to prove its useful features. Second, I describe in detail the 
results of QueryFuse in simulation data, cell line data and patient data. Then I discuss and 
summarize these results. Lastly, I present the performance estimation results of PREF 
from simulation data, and show an application example in a patient dataset.  
Chapter 6 summarizes the contributions discussed in this dissertation, and 
describes potential future improvements on the work presented here. 
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CHAPTER 2: OVERVIEW OF THE PROPOSED METHODOLOGIES 
 In this chapter, I review in detail the relevant concepts and methods necessary for 
the presentation of our methodologies. In Section 2.1, I introduce the regular workflow of 
RNA-Seq data processing, related tools and challenges. In Section 2.2, I introduce the 
commonly used seed method in fusion detection, and I compare it with my own new 
split-searching algorithm. In Section 2.3, I briefly summarize existing RNA-Seq based 
fusion simulation datasets and the challenges of simulating fusion from RNA-Seq data. In 
Section 2.4, I describe concepts that enable in silico validation of fusion. 
I open by giving essential definitions used throughout this section (Figure 2.1).  
I define a fragment as a contiguous sequence of nucleotides from a cDNA 
molecule. I define a read as a sequenced end of a fragment. I define paired-end 
sequencing as the protocol of sequencing both ends of the same fragment, and the two 
sequenced ends as paired ends. I define the non-sequenced fragment portion between 
paired ends as insert region, and its length as insert-size. If the insert-size is negative, the 
paired ends overlap. I define as paired-end-aligned (PEA) those reads in which both 
members of the pair are properly aligned to the reference. Similarly, single-end-aligned 
(SEA) denotes those read pairs where only one of the ends is properly aligned. I define a 
read as unmapped when it is not properly aligned. In paired-end sequencing, a SEA read 
should always have a corresponding unmapped read. It is also possible that both paired-
ends are unmapped, which is called both-end-unmapped (BEU), especially when the 
insert-size is negative. I define fusion boundaries as the precise, nucleotide-level genomic 
coordinates of the breakpoints on both sides of the fusion gene pair. I define as fusion 
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supporting spanning reads those PEA reads that have the fusion boundaries in the insert 
region, whereas a splitting read denotes a read with the fusion boundaries within its 
length. I define a >30-bp-long sequence that occurs multiple times across the genome as a 
high similarity region. 
 
Figure 2.1: Definition of essential terms. a) A blue bar stands for a sequenced read. The pink and purple 
bars are two strands of a fragment. The arrow points in the sequencing direction, and a read is always on 
the 5’ end of a strand. If only one read is sequenced per fragment, it is single-end sequencing and the read 
is called ‘single-end read’. If each fragment has two sequenced reads, it is paired-end sequencing and the 
pair of reads is called ‘paired-end reads’. b) The green boxes stand for exons and the black strings stand for 
introns. For paired-end sequencing, if only one read of a pair is properly aligned to the reference (generally 
on exon in RNA-Seq data), it is called single-end-aligned (SEA). On the other hand, if both reads of a pair 
are properly aligned, it is called paired-end-aligned (PEA). c) The red string indicates a pair of fusion 
boundaries on gene X and gene Y (generally in the intron region in DNA). From RNA-Seq, a fusion gene 
XY will present as two exons fused together. Spanning reads are those PEA reads that have the fusion 
boundaries in the insert region, whereas a splitting read denotes a read with the fusion boundaries within its 
length. 
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Section 2.1: RNA-Seq Data Processing Pipeline 
As a high-throughput technology, RNA-Seq generates massive amounts of data, 
thus making data management and interpretation challenging and requiring a series of 
computational tools for different research purposes (Figure 2.2). An automated pipeline 
for RNA-seq data analysis and quality assessment can significantly save time and labor 
and allow for the early detection of poor-quality samples.  
 
Figure 2.2: RNA-Seq data processing workflow. Sequencing data is the primary input. Before doing 
sequence alignment/mapping, sequencing quality control is executed. Then alignment quality control is run 
on the aligned data. With aligned data, users can move on to quantification analysis and/or structure 
analysis based on their research interests. In quantification analysis, which focuses on expression level of 
transcripts, expression quantification and normalization is the primary data processing. Downstream 
functional analysis includes differential expression, alternative splicing, etc. Structure analysis, which 
focuses on structure changes, includes structure variation (fusion, mutation, etc.) analysis and other de novo 
discoveries. 
The first step of RNA-Seq data analysis is quality control on sequencing data. 
Although sequencing technologies (e.g., Illumina (Illumina n.d.), Ion Torrent (Ion 
Torrent n.d.)) are quite reliable now, quality control, including PCR artifact, CG content, 
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duplication rate, sequencing quality score, and adapter enrichment is still necessary. From 
the report of quality control, one can determine how reliable a sequencing run is and 
decide whether a run is usable or requires re-running. FastQC (Andrews n.d.) is a widely 
used quality control tool for the FASTQ file, a uniform format of raw sequencing data.  
Although FastQC reports tables and figures to show the quality of each run, it is time-
consuming and fallible to check these reports manually, especially when the sample size 
is huge. As a result, generating a summary report across samples and flagging low-
quality samples are important in the RNA-Seq pipeline.  
The second step is sequence alignment, which indicates where each read is from 
the transcriptome. Because transcription has complex mechanisms, including splicing and 
RNA-editing, alignment of RNA-Seq data is different from DNA-Seq data. A few RNA-
Seq aligners (Garber et al. 2011) (e.g., TopHat (Trapnell et al. 2009), STAR (Dobin et al. 
2013), and MapSplice (Wang et al. 2010)) were developed with different focuses, but 
none of them is dominant. The good news is that the output format of these aligners is 
uniform and called the “Sequence Alignment/Map” (SAM/BAM) (Genetics n.d.). 
Consequently, to make the pipeline flexible, users should be able to select the appropriate 
aligner, when downstream analyses take SAM/BAM as the standard input.  
Checking alignment quality is as important as quality control on raw data. 
Because sequence alignment requires heavy computational resources (e.g., CPUs, RAMs, 
and disk space), it is a sensitive step and easy to fail. Additionally, the report of 
alignment statistics (including alignment percentage, mismatch rate, and multiple 
alignment) is an important feature to evaluate the quality of a sample. Therefore, similar 
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to sequencing quality control, generating a summary report across samples and giving 
alarm on low-quality samples are necessary. After this step, the basic data processing is 
done and the downstream is functional analysis. 
There are two main uses of RNA-Seq data: quantification analysis and structure 
analysis.  
Quantification analysis reports the expression level of gene and/or transcripts. 
There are different ways to normalize and compare expressions within and across 
samples, such as Fragments Per Kilobase per Million (FPKM), Reads Per Kilobase per 
Million (RPKM), log transformation on raw read counts, etc. Thus, different tools using 
these methods were developed (Garber et al. 2011; Trapnell et al. 2012) (e.g. Cufflinks 
(Trapnell et al. 2010), RSEM (Li & Dewey 2011), HTSeq (Anders et al. 2014) and 
EdgeR (Robinson et al. 2010)). However, the choice of tool often depends on the analyst, 
and new tools are bound to be developed. Therefore, a good pipeline should allow for the 
adoption of multiple methods, with the final choice of which method to use left to the 
user.  
One advantage of using RNA-Seq is that it enables structure analysis, by which 
the user can study structural changes of the transcriptome.  Fusion detection is the most 
popular field in structure analysis from RNA-Seq data. I will give a detailed introduction 
to RNA-Seq based fusion detection in Section 2.2. Other than fusion detection, mutation, 
RNA-editing and transcriptome assembly are not as developed but they are receiving 
increasing attention.  
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The user friendliness is an important feature of any RNA-Seq pipeline. Ideally, 
the software should be portable – i.e., easily installable, including all its dependencies –, 
and platform agnostic – i.e., independent of a specific operating system. Lastly, because 
RNA-Seq data processing is computationally expensive and time-consuming, the 
software ability to take advantage of parallelization is also desirable. 
In summary, for RNA-Seq data processing, sequencing quality control, sequence 
alignment, alignment quality control and quantification analysis are the main tasks to 
include in a pipeline. The main purpose of a pipeline is to save time and labor by 
automation, summary reporting and warnings. Other user-friendly features, such as 
portability, platform independence and parallelization, are additional desirable features. 
Section 2.2: QueryFuse—A Gene Specific Fusion-Detection Algorithm 
As mentioned in Section 1.1.3, there have been more than 18 RNA-Seq based 
fusion-detection algorithms. Generally, they can be categorized into two groups: 
fragment based approaches and pseudo-reference based approaches. The key difference 
between the two approaches is what is used as reference. Fragment based approaches use 
only the provided reference, while pseudo-reference based approaches also make use of 
the pseudo-reference generated by de novo assembling.  In common, both approaches 
split reads into fragments to detect fusion breakpoints. Although each algorithm has its 
own tricks including how to split reads, most of them use the seed method. The seed 
method randomly splits each of the target reads into smaller “seeds” (small reads with a 
fixed length), and then aligns these seeds to the reference. By combining the alignments 
of the multiple seeds from a read, the program can also determine whether a read is split 
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between two different genes. The seed method is relatively computationally expensive, 
because many seeds are generated to get enough sample size and only some of them can 
be aligned.  
My approach to aligning fusion-spanning reads is different, and is specifically 
tailored to the handling of splitting reads. As shown in Figure 2.1, each splitting read pair 
consists of one end aligning entirely to a given gene (the unsplit end), and one end split 
between two genes (the splitting end). Importantly, one portion of the splitting end aligns 
to the same gene as the unsplit end (gene X in Figure 2.1), and my fusion detection takes 
advantage of this information. Specifically, 1) it first determines the gene to which the 
unsplit end aligns; 2) it then performs a local alignment of the splitting end to that same 
gene; 3) finally, it performs a global alignment of the of splitting end portion that did not 
align by the local procedure. The reliance on a local alignment (step 2) allows for the 
adoption of a more accurate local aligner, such as blat, and thus reduces the chances of 
false positives. 
In principle, this algorithm could be adopted within a global fusion detection 
algorithm. However, my focus in this dissertation is on the gene-specific fusion detection 
problem – the detection of fusion partners for one or few selected genes of interest – 
which is extremely useful for biologists, and serves as a proof of concept of the proposed 
approach. To this end, I developed QueryFuse. To the best of my knowledge, QueryFuse 
is the first and only gene-specific fusion detection algorithm currently available. 
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Section 2.2: SimFuse—An RNA-Seq Based Fusion Simulator 
Within the 18 fusion-detection tools listed in Table 1.1, half of the methods 
(EricScript (Benelli et al. 2012), defuse (McPherson et al. 2011), Fusionfinder (Francis et 
al. 2012), FusionMap (Ge et al. 2011), FusionSeq (Sboner et al. 2010), FusionQ (Liu et al. 
2013), ShortFuse (Kinsella et al. 2011), SOAPfuse (Jia et al. 2013) and TophatFusion 
(Kim & Salzberg 2011)) used RNA-Seq based fusion simulation data for performance 
estimation, which shows the importance of simulation data in tool development. 
EricScript, deFuse, Fusionfinder, FusionMap, FusionSeq, SOAPfuse and ShortFuse used 
their own simulation data, while TophatFusion used the one from FusionMap and 
FusionQ used EricScript’s method to simulate. Only FusionMap’s simulation dataset is 
publicly available, while all the others had just brief descriptions in their methods 
sections. However, FusionMap’s dataset has only one sample with 50 fusions of various 
supporting read numbers, which is not enough to gain statistical power. EricScript has an 
integrated function to simulate a limited number of fusion reads, but systematic 
simulation of fusion data with statistical power is not available.  
The main challenge when generating simulated data is how to control for true 
positives and true negatives while maintaining a realistic background distribution that 
accurately models the multiple sources, often correlated, of noise. In fusion simulation, 
sources of randomness mainly include breakpoints location, fragments’ length of a 
splitting end, and mutations (i.e., differences from the reference genome). Generally, 
random breakpoints can be easily simulated. Random fragment lengths of the splitting 
end have to be constrained so as to avoid generating excessively short, hence un-
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alignable fragments. Therefore, users should have the ability to control the fragments’ 
length on the splitting end to ensure that simulated true positives are detectable. Random 
mutation is the hardest to mimic realistically, because mutation rates vary across the 
genome and currently it is not fully understood. The presence of mutations can turn a true 
positive fusion into a negative. Thus, the mutation rate in simulations should be carefully 
controlled. 
To achieve systematic and statistically powered estimation of the performance of 
fusion-detection algorithms, depending on the number of features to control, the 
simulation sample size can be significantly large. For example, just to assess the 
supporting read-specific performance by controlling the number of splitting and spanning 
with a specific ratio, at least three simulations (the general number of replicates in 
biological experiments) with 100 fusions (to reach 1% accuracy) are required. Meanwhile, 
to estimate statistical distribution, replicates (R) are necessary. In this case, at least 3 × 
100 × R fusions are needed. If different mutation rates are considered, the sample size 
will grow even larger. As a result, a well-designed RNA-Seq based fusion simulator, 
which is able to automatically and systematically generate simulation data with the right 
size, is needed.  
Section 2.4: PREF—An in silico Fusion Validation Tool 
Fusion detection is becoming a general component in cancer transcriptomic 
research using RNA-Seq data. The gold standard to validate detected fusion is by a series 
of experiments, including fluorescent in situ hybridization (FISH), rapid amplification of 
cDNA ends (RACE) and PCR. All these methods require well designed probes and effort 
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and time for conducting experiments. Therefore, correctly narrowing down the fusion 
candidates to the most reliable ones is required by biologists. A traditional way for 
biologists to computationally develop confidence about detected fusions is to look for 
supporting reads from an integrated genomics viewer (IGV) around the fusion 
breakpoints. However, this approach is subjective and laborious. It is surprising that there 
is no existing computational method that can make use of RNA-Seq data to validate 
detected fusions.  
In theory, a computational validation of a fusion is to reanalyze the reliability of 
this fusion by its detected supporting reads, that is, to eliminate false positive reads and 
find false negative reads. In the perfect scenario, a fusion detector reports all fusions with 
no false positive or false negative reads. However, in practice, fusion-detection tools 
detect false positive reads mainly because of misalignment and miss false negative reads 
mainly because of filtering. Therefore, a method that can address these two problems can 
be used to validate detected fusions because the reported supporting reads by this method 
is more reliable. 
One of the challenges of fusion detection is that the correct reference sequence of 
a fusion is unavailable. However, in fusion validation, this is no longer a problem 
because for each detected fusion, the fusion sequence must be easy to extract. Therefore, 
the detected fusion sequence can be used as the putative reference, and a regular 
sequence aligner can be used to align reads to this reference instead of to a genome. This 
targeted approach should improve the sensitivity and specificity of the detection of fusion 
supporting reads. 
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CHAPTER 3: METHODOLOGIES 
 This chapter is devoted to the detailed description of my four developed tools. 
The basic definitions (Chapter 2) are useful in this chapter as well. In Section 3.1, I 
introduce the workflow of our RNA-Seq pipeline, Hydra. I did the original development 
of the basic version of the RNA-Seq pipeline, and Daniel Gusenleitner and Vinay Kartha 
in our lab did the further software engineering and packaged it as Hydra. Thus, I show 
mainly my original work in this dissertation, with a brief introduction of some updated 
features in Hydra. In Section 3.2, I describe the workflow of QueryFuse in detail. In 
Section 3.3, I present SimFuse on how to simulate RNA-Seq based fusions from real data. 
Section 3.4 is devoted to the description of the workflow of PREF. 
Section 3.1: RNA-Seq Data Processing Pipeline 
 In Section 2.1, I described the regular workflow and key components of an RNA-
Seq pipeline. Here, I start with the brief description of the pipeline wrapper, and then I 
detail the four main components of Hydra: sequencing quality control, sequence 
alignment, alignment quality control and quantification analysis. 
 To process multiple samples at a time, the input of Hydra includes not only the 
raw sequencing data (FASTQ), but also an annotation file (Appendix file 1) including 
names of samples, step control, parameters for running modules, etc. The original 
wrapper was written in shell script. But to achieve better portability, platform agnostics 
and parallelization, Hydra is written in Python as an anaconda (Continuum Analytics 
n.d.) package. All the steps are wrapped into modules and the whole workflow is shown 
in Figure 3.1. 
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Figure 3.1: Workflow of Hydra. Hydra uses FASTQ file as the primary input and BAM file as the 
intermedia data format (marked in red). Tools used are listed in dark blue squares and the grey arrows 
direct the data flow. Black arrows point out the steps, in which check point summaries and error flags are 
sent to the final HTML report. 
 Sequencing quality control involves the steps from “fastq start” to the second 
“fastqc” in Figure 3.1. As mentioned in section 2.1, FastQC is generally used for quality 
control on FASTQ file. The running statistics and warnings are sent to the HTML report. 
Based on the first fastqc or primary experimental knowledge, if adaptors are enriched in 
the sample, adaptor trimming by cutadapt (Martin n.d.) and read pair matching by our 
customized script is necessary, and another fastqc will be run to check the quality after 
trimming. 
 The step of star/tophat in Figure 3.1 is the sequence alignment step. Currently, 
only STAR and TopHat are supported by Hydra, but more supporting modules for other 
state-of-the-art aligners will be developed. The alignment statuses of samples are sent to 
the HTML report, and then the user can decide whether to re-run the failed samples. 
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 Alignment quality control uses the BAM files from the alignment step as input. In 
the original version of my RNA-Seq pipeline, an ad hoc R script assembles alignment 
quality statistics (e.g., alignment percentage, mismatch rates, etc.) to flag poor-quality 
samples. In Hydra, a better developed tool—BamQC (Andrews n.d.) is used instead. 
Alignment quality summary and warnings are sent to the HTML report.  
Starting from this point, it is quantification analysis using the aligned BAM files. 
As mentioned in Section 2.1, there is no universal tool for quantification analysis. Thus, 
three different approaches (feature count, HTSeq (Anders et al. 2014), Cufflinks 
(Trapnell et al. 2010)) are used to give comprehensive expression profiling to the user. 
Summary plots from each approach are sent to the HTML report to help the user make 
decisions on downstream integrative analysis. 
  
Section 3.2: QueryFuse 
 QueryFuse consists of three main steps (Figure 3.2). 1) Extraction of fusion 
candidate reads involving the query gene from pre-aligned data. Given that realignment 
of all the reads for fusion detection is the most time-consuming step in other algorithms, 
QueryFuse uses pre-aligned data as the input to save time and make better use of existing 
information. 2) Classification of fusion candidates. Fusion candidate reads are carefully 
separated into different categories (Figure 3.3), with the reads in each category analyzed 
by category-specific methods aimed at maximizing fusion detection precision and recall 
rates.  3) Result summarization. The results from all categories are merged. To increase 
accuracy, several filters are applied to remove likely false positives. To help the user 
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interpret the results, I prioritize reliable fusions by feature-specific ranking across 
detected fusion events. In the last step, summary reports are automatically generated in 
both HTML and text formats. 
 
Figure 3.2: QueryFuse’s workflow. Step 1 is to split the pre-aligned BAM file into PEA and SEA reads. 
Step 2 is to extract spanning candidates from PEA reads and splitting candidates from SEA and unmapped 
reads. In Step 3, these candidates are summarized and filtered to get the summary of fusion events and to 
output the final report of fusion events after scoring and ranking. 
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Figure 3.3: Categories of fusion candidate reads. Red boxes stand for the query gene and blue boxes 
stand for the partner gene (which is generally unknown at this stage). The dashed line stands for the fusion 
boundaries. a) Paired-end processing category uses PEA reads as input and extracts only the PEA reads, 
those with one end aligned to the query gene and the other end aligned to the partner gene(s) as a pair of 
candidate spanning reads. b) Single-end processing category uses SEA reads and their complementary 
unmapped reads as input. To be a pair of candidate splitting reads, the SEA reads can be on the query gene 
or on the partner gene(s), while their complementary unmapped reads must be partially on the query gene 
with the other part on the partner gene(s). c) Unmapped pair processing category uses read pairs as input, in 
which both ends are unmapped. To be a pair of candidate splitting reads, the two reads should overlap and 
the fusion boundaries must be in the overlapped region. Additionally, the two reads must be sequenced 
from the opposite direction. Meanwhile, if the major portion of one end is on the query gene, the major 
portion of the other end must be on the partner gene. 
Section 3.2.1: Extraction of Fusion Candidate Reads Involving the Query Gene from Pre-
Aligned Data 
QueryFuse is designed to detect all candidate fusion events involving a given 
gene of interest (the query gene) from pre-aligned RNA-Seq data. In this study, although 
I used TopHat (Trapnell et al. 2009) aligned data as our input, output from other 
alignment methods can also be utilized. The aligned reads are separated into PEA and 
SEA reads. PEA reads partially aligned to the query gene are collected as spanning 
candidates. SEA and BEU reads partially aligned to the query gene from the local aligner 
are extracted as splitting candidates. (Now I use blat as the local aligner, but other local 
aligners, such as blast (Altschul et al. 1990), Stellar (Kehr et al. 2011)  will be supported 
in the future.)  
Section 3.2.2: Classification of Fusion Candidates into Different Categories 
Candidate fusion supporting reads are grouped into three categories (Figure 3).  
The first category is paired-end processing (Figure 3.3a). Only the read pairs, 
which have one end aligned to the query gene and the other end aligned to other genes, 
are retained as spanning read pairs. 
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The second category is single-end processing (Figure 3.3b), the most distinctive 
feature of QueryFuse algorithm. In a SEA read pair, I use the gene information from the 
SEA end to reliably locate the breakpoint location on the unmapped end. Because I am 
looking for fusion candidate reads involving the query gene, I assume that the unmapped 
end is composed by two parts: the piece from the query gene and the piece from an 
unknown gene. Thus, the unmapped ends in the SEA read pairs are locally aligned to the 
query gene to obtain the piece from the query gene. To confirm where the piece from an 
unknown gene is from, depending on where the SEA end aligned on, there are two 
subcategories: SEA end is on the query gene and SEA end is on the partner genes (Figure 
3.3b). If the SEA end is on the query gene, I globally align the piece from an unknown 
gene to the genome. If the SEA end is on the partner genes, I locally align the piece from 
an unknown gene to the gene that the SEA end is on, to confirm that the unknown gene is 
in fact the partner gene where the SEA end is found.  
The last category is unmapped pair processing (Figure 3.3c). If two ends of a read 
pair are overlapped and the fusion breakpoint is in this overlapped region, neither end can 
be aligned by the aligner. Given that fusion events involving the query gene are the 
targets, both ends of a read pair are aligned locally onto the query gene, then the 
unmapped portions are globally aligned to the genome. When the fusion boundaries of 
two genes, where both ends of a pair align, are the same, this read pair is considered a 
splitting read pair. Additionally, I use the characteristics of sequencing direction and 
splitting length as criteria (Figure 3.3c). 
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Section 3.3.3: Result Summarization 
To summarize the result at the fusion event level, spanning and splitting reads for 
each fusion event are merged together by their alignment location information. For each 
fusion event, since the fusion boundaries of its splitting reads should be the same, 
QueryFuse (QF) uses fusion boundaries of splitting reads (from the single-end processing 
category and the unmapped pair processing category) as the representatives of fusion 
events and keys to search for complementary spanning read pairs. 
To evaluate the number of multiple-alignments for each fusion event, a consensus 
fusion sequence is generated using all the supporting splitting reads (N), and it is locally 
aligned to the genome. If the consensus sequence can be aligned equally well to M 
different locations in the genome, I consider these locations as multiple-alignment. The 
splitting reads number for each alignment location of this fusion event equates to N/M 
(Figure 3.4). If the alignment on query gene and the alignment on the fusion partner gene 
have an overlapped region, I define this region as the ‘shifted region’ (which means 
shifting the breakpoint location in this region will not change the fusion sequence) and its 
length as ‘shifted range’ (Figure 3.5). The fusion breakpoint will be adjusted to the 
middle of this region. Otherwise, there is no fusion breakpoint adjustment for this fusion 
event because the ‘shifted range’ is zero. Additionally, the consensus sequence is 
essential to eliminate false positives caused by sequence similarity. If the consensus 
sequence aligns well on the fusion partner gene (<23 bp unmapped), this fusion event is 
considered as a false positive, because, in this case, the consensus sequence can come 
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solely from the fusion partner. It was considered a fusion candidate just because the 
query gene has a long homologous region with this fusion partner.  
After adjusting fusion boundaries of fusion events, spanning reads (from the 
paired-end processing category) are assigned to related fusion events. If a fusion event 
has M multiple alignments but only M’ out of M have corresponding spanning reads, the 
multiple-alignment number will be adjusted to M’ instead of M (Figure 3.4). The rest of 
the spanning reads, which are not assigned to any fusion events with splitting reads, are 
self-grouped into spanning-only fusion events by their alignment locations. 
To reduce false positives, all the reported fusions are filtered by user-defined 
parameters including the minimum requirement of splitting, spanning and total 
supporting reads.  
 
Figure 3.4: Condition of multiple-alignment. For each detected fusion event, all its splitting reads (light 
blue) are used to build the representative consensus sequence of the fusion product from two genes. This 
consensus sequence must have a portion that can align to the query gene (red), while the other side of the 
consensus sequence aligns to other locations (dark blue) on the reference. If the number of location(s) is 
greater than one, this fusion event has multiple-alignment. In this case, all locations (e.g., 3 in this case) are 
recorded and matched to alignment regions of corresponding spanning reads (white). Only the one(s) 
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supported by alignment regions of most spanning reads (i.e., Loc 3) is extracted as the representative of the 
fusion event. 
 
Figure 3.5: Breakpoint adjustment of the consensus sequence. When the consensus sequence is locally 
aligned to the query gene (red) and all other detected potential partners (blue), the two alignments can have 
a small overlap region (i.e., AGG) around the fusion breakpoint. Because the sequence of this region is the 
same on the two alignments, no matter where the fusion breakpoint is in this region (e.g., A-GG or AG-G), 
the fusion product is not changed. As a result, the size of the overlap region is called the shifted range and 
the breakpoint is adjusted to the middle of this region as the representative of the fusion event. 
To prioritize important and reliable fusions, seven features are used to rank and 
reorder the result: 
1. Number of splitting reads. 
2. Number of spanning reads. 
3. Total number of supporting reads (sum of splitting and spanning reads). 
4. Degree of dispersion of splitting reads. In theory, a sample without PCR 
artifacts should have uniformly distributed splitting reads around the breakpoint 
(Appendix Figure 1). As a result, the p-value from the Kolmogorov-Smirnov (KS) test is 
used to evaluate how similar the distribution of splitting reads is to a uniform distribution. 
5. Sequence similarity around the breakpoint of the fusion gene pair. From 
literature, I find that many validated fusions have a “‘shifted region” (Villarreal et al. 
2012). As a result, I use ‘shifted range’ to evaluate the similarity around the breakpoint of 
the fusion gene pair. However, if the shifted range of a fusion is longer than 23 bp, I 
consider it a false positive with a homologous region and filter it out. 
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6. Sequence complexity around the breakpoint in 30-bp range, measured by the 
dinucleotide entropy E: 
    E = ∑ −𝑃𝑖 ∗ ln (𝑃𝑖)
16
𝑖=1  
    The sum is over the 42 = 16 possible dinucleotide combinations. Pi denotes the 
frequency with which the ith combination occurs in the 30-bp range. 
    Low entropy corresponds to low complexity. I filter fusions with entropy ≤0.7 
(2 × -0.5 × ln(0.5) = 0.69, which stands for the extreme scenario when the sequence is 
composed of only two types of dinucleotide, e.g. 
AAAAAAAAAAAAAAATATATATATATATAT). 
7. Multiple alignments number. Fusions with a single alignment location are 
deemed most reliable. Conversely, the more alignments a fusion has, the less reliable it is. 
Each fusion is assigned a score Srank equal to the sum of the ranks of the features 
just described, Srank = Rsplit + Rspan × 2 + Rtotal + Rdispersion + Rshifted_range + Rcomplexity + 
Rmultiple_alignment, with R(X) denoting the rank of the X feature. The rank of spanning read 
number (Rspan) has a weight of 2 because generally Rspan is twice important as the other 
features. This is because in a regular library preparation procedure, the insert size is 
negative, which make fusions with spanning reads a strong indicator of true positives.  
Section 3.3.4: Implementation, Availability and Data Resources 
QueryFuse is implemented in shell script, python, perl and R. A run with one 
query (60 kb) on 52 million paired-end reads is completed in approximately 215 min (80 
min preprocessing and 135 min querying) using one core in an eight-core 2.6 GHz Intel 
Xeon E5-2670 processor with 64 GB memory. The preprocessing time and the querying 
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time are dependent on read number and the querying time is dependent on the query gene 
length as well. QueryFuse is able to run parallel among different queries with multiple 
processors. 
The human genome (hg19) was downloaded from the Tophat website. A gene 
annotation file of hg19 was downloaded from biomart with a focus on protein_coding as 
gene type (http://useast.ensembl.org/biomart/).  
To rescue potential gene fusions with partners partially falling outside the gene 
annotation region, an expanded gene annotation file was generated from the regular gene 
annotation file by extending the reference sequence of each gene by 5,000 base pairs both 
upstream and downstream of the gene region.  
All data files and reference datasets are available as part of the QueryFuse 
software package in github (https://github.com/yuxiangtan/QueryFuse). 
Section 3.3: SimFuse 
 The input to SimFuse consists of a pair-end aligned BAM file with known read 
length and distribution of fragment lengths (the insert-size must be positive in order to 
simulate spanning reads following this distribution). SimFuse consists of the following 
four modules (Figure 3.6): 
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Figure 3.6: SimFuse workflow. a) Fusion free reads are extracted from the real data. b) The expression 
profile from real data and a genome reference are used to simulate fusion reads. c) Fusion-free reads and 
simulated fusion reads are merged. d) Running fusion-detection algorithms on this simulation dataset 
generates results of detected fusions. By comparing these results with the list of simulated fusions, users 
can estimate the performance (recall and precision) of algorithms. 
1. Extraction of fusion-free reads from the input BAM file, to build the background read 
distribution. Generally, a real dataset from patients or cell lines is preferred. The 
benefit of using real data to generate the background is that it mimics the background 
noise in real data and also captures the realistic variation in gene expression levels. 
To filter all the potential fusion-supporting reads from the real data, only the pair-end 
aligned reads consistent with the distribution of fragment lengths are kept. 
2. Simulation of fusion supporting reads. To fully control the simulation, SimFuse uses 
a genome reference (e.g., hg19.fa) as the template to generate supporting reads for 
simulated fusions (Figure 3.7). First, genes are binned into M expression subgroups 
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based on the corresponding number of raw reads in the input data. The default setting 
of M expression subgroups corresponds to raw read counts in [0 ~ 10), [10 ~ 102), 
[102 ~ 103), … , [10M-1 ~ 10M]. For each expression subgroup, N (the number of 
fusions to be simulated in a group; N=100 as default) genes are randomly picked 
without replacement as the fusion genes. For each fusion gene, a fusion gene partner 
is randomly selected from each of the expression subgroups. For each pair of genes, 
splitting and spanning read pairs are simulated by using the reference sequence of 
these genes. For each exon picked, the region to generate simulation reads is read-
length × 3 around an exon boundary. For spanning read pairs, one spanning read will 
be randomly generated on each partner while the whole pair must follow the 
distribution of fragment length. For each splitting read, a random length is picked for 
one partner and the complementary length is generated on the other partner. An 
accompanying spanning read following the distribution of fragment lengths will be 
randomly generated to fit the splitting read into a pair. Based on the fragment size 
distribution, the ratio of the number of splitting reads to the number of spanning reads 
(splitting to spanning read ratio) should follow the equation: #splitting/#spanning = 
read_length × 2/(fragment length – read_length × 2). At the end of this process, a 
total of M × N × M fusion events are generated, with N fusion events for each of the 
M × M combinations of expression groups. Finally, all the simulated reads are 
merged with the background reads into a newly created FASTQ file, and a list of 
fusion-gene pairs is generated. 
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Figure 3.7: Workflow of generating fusion supporting reads. An exon in gene X and an exon in gene Y 
are randomly picked. Exon boundaries are used as the fusion boundaries. Spanning reads are randomly 
generated within the range (read-length × 3 as default) from the boundaries. To generate a splitting read, 
one piece around each of the two boundaries, which sum up as the read-length, are merged together. A 
spanning read is randomly generated from either of the two exons to match the splitting read into a splitting 
read pair. 
3. Wrapper for the automatic simulation of multiple datasets with different supporting 
reads. To fully estimate the performance of a fusion detection algorithm, a simulated 
dataset with great enough sample size is needed. Additionally, the performance of a 
fusion-detection algorithm may vary depending on the different number of supporting 
reads. To be user friendly, SimFuse has a wrapper function that simultaneously 
generates K simulations with L different combinations of supporting read numbers, 
which turn out to be a total of M × N × M × L × K fusion events. 
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4. Generation of a summary of fusion detection results from algorithms for the whole 
simulation. To compare fusion detection results from different algorithms efficiently, 
I convert these results to a uniform format and then use a SimFuse function for 
summarization (Figure 3.8). 
 
Figure 3.8: Workflow of performance summarization on results from fusion-detection algorithms. To 
get the TPs and FPs, for each fusion-detection algorithm, the fusion result is compared with the list of 
simulated fusions. Precision and recall rates are calculated using the number of TPs and FPs. Performance 
summary plot is generated using the precision and recall rates from algorithms. 
 To estimate the performance of a fusion-detection algorithm, I use recall and 
precision rates instead of sensitivity and specificity. Precision is more informative than 
specificity, since in fusion detection the number of true negatives (TN) is always much 
larger (~20K genes in the human genome(Ensembl n.d.)) than the number of true 
positives (TP). As a result, unless the number of false positives (type I errors) is 
extremely large, the specificity will always be close to 1, and will not adequately capture 
the difference among competing detection algorithms.  
Recall: true positive / (true positive + false negative) 
Precision: true positive / (true positive + false positive) 
  
37 
Section 3.4: PREF 
 PREF is an in silico and putative reference based fusion validation method. There 
are three main steps in PREF’s workflow (Figure 3.9): generation of the putative 
reference, sequence alignment to the putative reference (by Bowtie2 (Langmead & 
Salzberg 2012)) and summarization of supporting reads. 
 
Figure 3.9: Workflow of PREF. Putative reference is generated by merging read-length × 2 bp regions 
around the provided fusion breakpoints (Loc1 in gene1 and Loc2 in gene2). All the reads in the sample are 
used to align to the putative reference(s) by Bowtie2 (Langmead & Salzberg 2012). Supporting reads are 
exacted from the aligned reads and reported in a summary. 
 To generate the putative reference of a detected fusion, either the genomic 
locations of the fusion breakpoints or the reported fusion sequence from a detector can be 
used. These two ways are both supported by PREF. In most fusion detection methods, 
only fusion breakpoints are available, and thus this scenario is used as the example in the 
following descriptions. In Figure 3.9, Loc1 on gene1 and Loc2 on gene2 are known as 
fusion breakpoints. Then read-length × 2 bp-long regions next to these two breakpoints 
are exacted and merged together as the putative reference. Once the fusion breakpoint 
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locations of fusions to be validated are provided (generally they are directly from the 
output of a fusion detector), PREF will automatically generate putative references of 
these fusions. Because sequence alignment is the most time-consuming step, to be 
efficient, if multiple fusions are to be validated, all the putative references are gathered as 
a reference pool rather than aligning them one by one. 
Bowtie2 (Langmead & Salzberg 2012) is used as the default aligner for sequence 
alignment, because Bowtie2 is the state-of-the-art non-splice aligner for RNA-Seq data. 
The reason for using the non-splice aligner rather than the splice aligner (such as Tophat 
(Trapnell et al. 2009)) is that the goal of alignment is to find reads perfectly aligned to the 
putative reference, which are the candidates for fusion supporting reads.  
In the step of summarization of supporting reads, only the reads that are perfectly 
aligned to the putative reference(s) and across the fusion breakpoint for at least N bp are 
used as splitting reads, while only the read pairs, in which the two reads are perfectly 
aligned to the two sides of the a fusion separately, are considered as spanning read pairs. 
At the end, for each detected fusion, all the supporting reads are listed within an 
alignment plot to the putative reference.  
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CHAPTER 4: DATASETS  
As discussed in this chapter, to evaluate the performance of the proposed tools, I 
performed validation of three different kinds of datasets. In Section 4.1, two RNA-Seq 
based fusion simulation datasets are described. Section 4.2 introduces three cell lines with 
known fusions. Section 4.3 is devoted to the description of two patient datasets, including 
the source of samples, library preparation and biological motivations. 
Section 4.1: Simulation Datasets 
 Simulation data is important in performance evaluation for computational 
methods. Although simulation cannot fully regenerate all the features and factors as they 
are in the real cases, simulation datasets have confirmed true positives (TPs) and true 
negatives (TNs), which are the essential numbers for precision and recall calculation. 
 In this section, I introduce two simulated RNA-Seq fusion datasets. The SimFuse 
dataset was generated by SimFuse, which is one of our proposed tools, while the 
FusionMap dataset is the most accessible and popular simulation dataset.  
Section 4.1.1: SimFuse Dataset 
ENCODE MCF-7 cell line dataset (SRR521521) was used as the simulation 
background. This dataset consists of 76 bp pair-end reads, with a median fragment size of 
192 bp, and a standard deviation of 29 bp. Accordingly, I used a splitting-to-spanning 
read ratio of 19:5 (equals 76 × 2 ÷ (192 - 76 × 2)) for the generation of the fusion 
supporting reads. I next generated K = 100 independent simulations, and for each 
simulation, I generated L = 10 combinations of supporting read numbers, ranging from 1 
splitting read and no spanning reads (1:0) to 100 splitting reads and 26 spanning reads 
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(100:26), with N = 100 fusion events for each combination (Appendix Table 1). The 
expression profile is not considered and M = 1, because the data already has 100,000 (1 × 
100 × 1 × 10 × 100) fusions. The entire data generation procedure was run on a 16-core, 
2.3-GHz AMD Opteron 6276 machine with 64 GB memory. Because SimFuse does not 
currently support parallel processing, it took 18.5 hours to complete this task using a 
single core. 
Section 4.1.2: FusionMap Dataset 
This dataset is from FusionMap (Ge et al. 2011) and used as an external 
validation. Its read length is 75 bp and its mean fragment size is 158 bp. It has 57209 
paired-end reads and contains 50 simulated fusion events. 
Section 4.1.3: Criteria of Applying Simulation Datasets 
To obtain a fair comparison of results from different fusion-detection algorithms, 
the following criteria were applied: 
1. Only the filtered results were compared (both deFuse and QueryFuse have filtered 
and unfiltered results). 
2. Only chromosome, fusion boundaries and fusion direction were used as “matching” 
criteria. Gene names and gene IDs were not used because there could be more than 
one gene at the same location. 
3. The fusion direction was considered because for any gene1-gene2 fusion there could 
be two distinct fusion events associated with the same fusion boundaries: gene1 on the 
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5’ end with gene2 on the 3’ end; and, vice versa, gene1 on the 3’ end with gene2 on the 
5’ end.  
4. To qualify as a true positive fusion, the fusion’s detected boundaries must be within 
the 10 bp range of its simulated boundaries. 
 
Section 4.2: Cell Line Datasets 
 In this section, three publicly available RNA-Seq datasets on cell lines are 
introduced. The cell lines contain experimental validated fusions, which are used to show 
the detection power of fusion-detection algorithms. However, because of dynamic 
changes in cell lines and their expression profile, not all the validated fusions are 
detectable. As a result, I used the detected number of validated fusions as the 
representative of the sensitivity of each fusion-detection algorithm:  
1. Breast cancer cell line datasets (Edgren et al. 2011). I use BT-474, SK-BR-3 and 
MCF7 cell lines. The read length of this dataset is 50 bp, which is not optimal for 
QueryFuse. I found new sequencing datasets with longer read length (76 bp or 101 bp) 
for these 3 cell lines from DNAnexus Archive (see Appendix Table 2 for sample ID 
and read length distribution). There are 3 experimentally validated fusions in MCF7, 
10 in BT-474 and 7 in SK-BR-3. 
2. ALK fusion cell line datasets (Voena et al. n.d.). H2228 cell line is a non-small cell 
lung cancer (NSCLC) with ALK-EML4 and ALK-PTPN3 fusion. DHL cell line is a 
model of anaplastic large cell lymphoma (ALCL) with ALK-NPM1 fusion. I have 8 
sequenced samples in this dataset, 5 out of 8 are H2228 cell lines and the rest 3 are 
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DHL cell lines. Although they were treated with chemicals in the original paper, the 
representative fusions were not affected. As a result, I considered these samples as 
replicates of the two cell lines. 
3. Bladder cancer cell line datasets. In SOAPFuse manuscript (Jia et al. 2013), two 
bladder cancer cell lines are used to detect fusions and 15 fusion transcripts are 
experimentally confirmed. 
Section 4.3: Patient Datasets 
 In this section, two patient datasets, which are used as practical examples, are 
introduced. The description includes not only the experimental features but also the 
biological background with hypothesis.  
Section 4.3.1: Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft (DLBCL-
PDX) Model 
All DLBCL patient specimens were obtained from BC Cancer Agency with 
written informed patient consent, following a protocol approved by the Clinical Research 
Ethics Board of the University of British Columbia. Six- to eight-week-old male NOD 
SCID IL2Rgnull (NSG) mice (Jackson Laboratory) were used for the establishment of 
PDX models. All related experimental protocols were approved by the University of 
British Columbia Animal Care Committee (Chapuy et al. n.d.). Subrenal capsule PDX 
models were generated as previously described (Wang et al. 2005; Lee et al. 2005). In 
the end, nine DLBCL-PDX models were successfully generated. These nine models were 
RNA sequenced together with seven primary human DLBCL samples as control.  
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Sequencing libraries were prepared from total RNA samples using Illumina® 
TruSeq® RNA Sample Preparation Kit v2 following standard protocols. The mRNA was 
isolated using magnetic beads-based poly(A) selection, fragmented and randomly primed 
for reverse transcription, followed by second-strand synthesis to create double-stranded 
cDNA fragments with a median fragmentation size of 150 bp. These cDNA fragments 
were then end-repaired and a single ‘A’ base was added and the modified fragments were 
ligated to Illumina® Paired-End sequencing adapters. The products were purified and 
PCR-amplified to create the final cDNA library. The libraries from individual samples 
were pooled in groups of four for cluster generation on the Illumina® cBot using 
Illumina® TruSeq® Paired-End Cluster Kit. Each sample was sequenced on the 
Illumina® HiSeq 2000.  
Different from a genetically engineered mouse model, DLBCL-PDX can capture 
the genetic, transcriptional and functional heterogeneity of primary human DLBCL. 
Other than growing in culture media like cell lines, PDX models grow as tissues within 
the hosts, which should be more reflective and reliable. However, establishing PDX 
models of DLBCL has been historically difficult, and there is no existing study. 
Therefore, we established genetic and biological characterization of nine DLBCL-PDX 
models by RNA-Seq and compared them with primary DLBCL to evaluate PDX models’ 
similarity with primary disease tissue. 
Section 4.3.2: Patient Primary Lymphoma 
In accordance with the local IRB protocols, 16 fresh-frozen tumor samples from 
patients diagnosed with primary central nervous system lymphomas (PCNSLs) (10 
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patients) and primary testicular lymphomas (PTLs) (6 patients) were collected from 4 
institutions (Dana-Farber Cancer Institute, Brigham and Women’s Hospital, 
Massachusetts General Hospital, all Boston, MA, USA; University of Freiburg, Germany 
(Bjoern et al. n.d.). High molecular weight genomic DNA was extracted from all frozen 
tumors. Matched total RNA was extracted from these 16 samples. We processed WES on 
DNA and RNA-Seq on the matched RNA. RNA-Seq was run on Illumina® HiSeq 2000 
to generate paired-end 100-bp reads with a median fragment size of 150 bp. 
There are three important characters of these 16 samples: 
1. Different from diffuse large B-cell lymphoma (DLBCL) which is the most common 
lymphoid malignancy and typically in nodal organs, PCNSLs and PTLs typically 
presents in extranodal organs (Bjoern et al. n.d.; Cheah et al. 2014; Deckert et al. 
2014). Additionally, PCNSLs and PTLs both arise in non-lymphoid organs that were 
previously considered to be immune sanctuaries (Schuuring et al. 2014). 
2. In the 16 samples, a PTL sample (TL-03) was hypothesized to have a fusion of PD-
L2 with unknown fusion partner. PD-L2 is a ligand of the programmed death 1 (PD-1) 
pathway – an immune checkpoint pathway. As a new and powerful forms of 
immunotherapy, therapeutic blockage of immune checkpoint pathways has become a 
paradigm-shifting treatment (Armand 2015), in which PD-L2 plays an important role. 
By increasing the abundance of PD-L2 on the cell surface, tumors can co-opt the PD-
1 pathway to evade an immune response (Ansell et al. 2015). Thus, PD-1—blocking 
antibodies have been used in immunotherapy in solid tumors (such as melanoma, 
lung cancer, and renal cell cancer) and obtain durable clinical responses with an 
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acceptable safety profile (Armand 2015; Ansell et al. 2015) This therapeutic strategy 
is also used in certain hematologic cancers. For example, in Hodgkin lymphoma, a 
single-agent PD-1 blockade yielded overall response rates of 87% and 65% with 
nivolumab and pembrolizumab, respectively (Armand 2015).   
3. From the preliminary copy number variation (CNV) analysis result, we found a 
significant copy number gain peak on chr9 (Figure 4.1a). By zooming into this region, 
we found three samples (black arrows in Figure 4.1b) with partial copy number 
change within this region, while one of them (red arrow in Figure 4.1b, which is TL-
03) had the change within the gene region of PD-L2. In the expression profiling result 
from RNA-Seq data, TL-03 (red arrow in Figure 4.1c) has more than 100-fold 
overexpression of PD-L2. All these facts raised a fusion hypothesis that, in TL-03, 
PD-L2’s regulation elements were fused and replaced by the regulation elements 
from an unknown gene, which results in strong up-regulation of the expression of PD-
L2. 
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Figure 4.1: CNV and expression results in the lymphoma study. a) Copy number gain result across the 
genome in 210 lymphoma samples. The x-axis is the q-value, which represents significance. The y-axis (in 
the middle) shows the chromosomal location across the genome. The group on the left is DLBCL and the 
group on the right is PCNSL/PTL. Marked locations on the right-hand side show the important regions in 
PCNSL/PTL. Within them, the regions marked in red are the ones in PCNSL/PTL, significantly different 
from DLBCL. b) The CNV result zoomed in the 9p24.1 region. In this region, only five samples have copy 
number change. Three of them (black arrows) change only partially. Only one (red arrow) out of three has 
the change within a gene (PD-L2), while the other two have the changes right in front of the gene region. c) 
Expression profile of PD-L2 from RNA-Seq data of six PTL samples. In TL-03 (red arrow), which is the 
same sample marked in b), the PD-L2 expression is more than 100-fold up-regulated than all the other 
samples. 
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CHAPTER 5: RESULTS AND DISCUSSION 
This chapter is devoted to showing results and discussion of proposed methods. In 
Section 5.1, I use the PDX dataset (Section 4.3.1) as the practical example of using Hydra, 
the RNA-Seq pipeline. Section 5.2 shows the performance of QueryFuse on simulation 
datasets (Section 4.1), cell line datasets (Section 4.2) and the patient primary lymphoma 
dataset (Section 4.3.2). In Section 5.3, I present the sensitivity and specificity of PREF 
and its application to validate the detected fusions from QueryFuse on the patient primary 
lymphoma dataset (Section 5.2.3). 
Section 5.1: RNA-Seq Data Processing Pipeline 
Section 5.1.1: Sequencing Quality Summary 
  All 16 samples in the PDX dataset were run successfully through the pipeline and 
had very good sequencing quality, reported by FastQC. For the whole 99-bp-long reads, 
the mean and median of sequencing quality scores at each base were all above 28 (the 
green region, Appendix Figure 2), which was highly reliable. There was no enriched 
adaptor sequence or PCR artifacts. 
Section 5.1.2: Contamination of Mouse Tissues 
 
After sequence alignment using TopHat, the alignment quality summary was 
reported. As illustrated in the left side of Figure 5.1, I found a sample that had 
significantly low alignment to the human genome, an indication of mouse tissue 
contamination, which made me check its alignment to the mouse genome (right side of 
Figure 5.1). In the alignment summary of the mouse genome, the control samples had 
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nearly the same number of reads aligned to the mouse genome, which defined the base 
line of sequencing noise combined with sequence similarity between human and mouse 
genomes.  On the opposite, at least 4 out of 9 PDX samples had more alignments to the 
mouse genome than the base line. Additionally, in the most contaminated PDX sample, 
approximately 30% of the total reads aligned to the mouse genome, which is similar to 
the unaligned percentage to the human genome.  
 
Figure 5.1: Summary of read alignment numbers. The circled sample is the one with most mouse tissue 
contamination. Red bars show the number of reads unaligned. Green bars show the number of reads that 
have multiple alignment locations. Blue bars show the number of uniquely aligned reads. The x-axis is 
indexed by sample ID and grouped separately into PDX and control groups. The y-axis reports the number 
of reads in million. On the left is the summary of alignment to the human genome, while on the right is the 
summary of alignment to the mouse genome. The dashed line represents the background noise of 
sequencing combined with the sequence similarity between the human and mouse genomes. 
In the mismatch overview of reads aligned to the mouse genome (Figure 5.2), 
much higher percentages of aligned reads were perfectly aligned in PDX samples (>20%) 
than those in the control samples (< 5%). This fact further supported the assumption of 
the mouse tissue contamination in PDX samples. 
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Figure 5.2: Mismatch overview of reads aligned to the mouse genome. Seven colors represent 
separately the percentage of aligned reads with 0 to 5 and >5 mismatches. The x-axis is indexed by sample 
ID and grouped separately into PDX and control groups. The y-axis reports the percentage of each color 
group. In most PDX samples, more than 20% of aligned reads are perfectly aligned (without mismatch) to 
the mouse genome, while fewer than 5% of aligned reads are perfectly aligned to the human genome. 
Section 5.1.3: Discussion 
To get a comprehensive understanding of a RNA-Seq study, many summary plots 
automatically generated by Hydra are crucial, although only a portion of these summary 
plots in the HTML report were showed to support the mouse contamination statement. 
The remaining plots were just showing the runs and the results were good, instead of 
being a flag of problems, but they were necessary. With the help of these plots, I saved 
time on checking the quality of runs and samples. Meanwhile, because the pipeline runs 
jobs consecutively, I saved time on responding to the finished jobs after each run. In 
summary, the pipeline speeded up all my RNA-Seq based projects by effectively 
managing the primary data processing from RNA-Seq data. 
A comprehensive quality-summary report is important in guiding the downstream 
data analysis. Although most RNA-Seq data has high quality, to eliminate noise, it is 
crucial to filter outliers with low qualities, which is reflected in the quality summary. In 
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some cases, such as the mouse tissue contamination example, the low quality is caused by 
adjustable factors. Consequently, these factors must be adjusted before downstream 
analysis. In the PDX study, I used my ad hoc contamination filter to eliminate all 
potential mouse contamination reads, which resulted in an expression profile with much 
less noise for the downstream differential expression analysis. 
Section 5.2: QueryFuse 
In this section, QueryFuse is first validated and compared with two popular 
fusion-detection tools (defuse (McPherson et al. 2011) and TophatFusion (Kim & 
Salzberg 2011)) by simulation data and cell line data. Then QueryFuse is used in the 
lymphoma study (Section 4.3.2) to validate the PD-L2 fusion hypothesis. Meanwhile, 
deFuse and TophatFusion are used as a second opinion.  
Section 5.2.1: Estimation of Recall and Precision Rates from Simulated Data 
To estimate both recall and precision rate (Powers 2011), I used SimFuse datasets 
(Section 4.1.1) to compare performance of QueryFuse, TophatFusion and deFuse. Figure 
5.3 and Appendix Table 3 and 4 show the comparison of the results of the three methods. 
QueryFuse had the highest recall and precision across all combinations of supporting 
reads. The highest recall achieved by QueryFuse, TophatFusion and deFuse were 90%, 
84% and 85%, respectively. The precision rates for QueryFuse and deFuse peak at 99% 
and 95%, respectively. Of notice, TophatFusion’s precision rate showed a slight decrease 
as the number of supporting reads increases. This might be because the risk for 
TophatFusion to detect multiple alignment events increases as the number of supporting 
reads increases. Additionally, QueryFuse and TophatFusion could detect fusions with as 
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low as 4 supporting reads (3 splitting and 1 spanning reads). On the other hand, deFuse 
needed approximately 20 splitting and 5 spanning supporting reads to achieve a 
reasonable detection performance (75% recall and 95% precision rate).  
 
Figure 5.3: Barplot of recall and precision rates for QueryFuse, TophatFusion and deFuse. Red bars 
indicate QueryFuse results, blue bars indicate deFuse results and yellow bars indicate TophatFusion results. 
The x-axis is indexed by the supporting read groups with each group corresponding to the indicated 
splitting-to-spanning read ratio. The y-axis reports precision and recall rates. The upper and lower whiskers 
represent the upper and lower limits of the confidence interval at 95% confidence level. The red dashed line 
shows estimates for QueryFuse from the FusionMap dataset, the yellow dashed line shows estimates for 
TophatFusion and the blue dashed line shows estimates for deFuse. 
For the external simulation dataset from FusionMap (Ge et al. 2011) (Section 
4.1.2), QueryFuse had the highest recall (36/50 = 72%) and precision (36/37 = 97.3%). 
TophatFusion was the second (recall is 35/50 = 70% and precision is 35/36 = 97.2%). 
deFuse’s recall was 34/50 = 68% and its precision was 34/35 = 97.1%.  
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Section 5.2.2: Application to Cell Line Datasets 
For breast cancer datasets, the numbers of experimental validated fusions in cell 
lines were 10 in BT-474, 7 in SK-BR-3 and 3 in MCF7 (Edgren et al. 2011) (Appendix 
Table 2). In the 50-bp-long dataset, which was original from the Edgren et al. paper, 
deFuse performed the best (7 in BT-474, 4 in SK-BR-3 and 3 in MCF7). The default of 
QueryFuse (6 in BT-474, 3 in SK-BR-3 and 3 in MCF7) performed similarly to 
TophatFusion (5 in BT-474, 4 in SK-BR-3 and 2 in MCF7). Because 50 bp is too short 
for QueryFuse to detect splitting reads efficiently and the theoretical splitting:spanning 
read ratio in BT-474 and SK-BR-3 are 1:1, some validated fusions were supported by 
only spanning reads in QueryFuse. If these fusion events were considered as QueryFuse’s 
extended result, QueryFuse (7 in BT-474, 4 in SK-BR-3 and 3 in MCF7) performed 
equally well as deFuse. The validated fusions missed by all three algorithms (2 in BT-
474, 2 in SK-BR-3 and 0 in MCF7) have low supporting read numbers, which make them 
undetectable. To get data with optimal read length for QueryFuse, I found RNA-Seq 
datasets for these three cell lines with longer read length. However, many validated 
fusions in these three cell lines were not detected (6 in BT-474, 3 in SK-BR-3 and 0 in 
MCF7), which showed potential batch effects from the variety of cells in the cell lines. 
The default of QueryFuse worked as well as deFuse (3 in BT-474, 3 in SK-BR-3, and 3 
in MCF7), while TophatFusion detected one more fusion in SK-BR-3 than the others. 
CCDC85C-SETD3 fusion was also detected in SK-BR-3 by QueryFuse but supported 
only by spanning reads. The potential explanation is that this fusion has a low supporting 
read number and the theoretical splitting:spanning read ratio in this sample is 7:4, which 
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makes it possible that there were no detectable splitting reads of this fusion from 
QueryFuse. 
In ALK dataset, all five H2228 samples have ALK-EML4 and ALK-PTPN3 
fusions and three DHL samples have ALK-NPM1 fusion (Appendix Table 5). deFuse 
detected all these fusions, while QueryFuse missed one fusion event and TophatFusion 
missed three fusion events. 
In the bladder cancer cell line dataset (Appendix Table 6), deFuse, TophatFusion 
and QueryFuse performed equally well (3 out of 8 in SRR497884 and 3 out of 7 in 
SRR497885).  
In summary, although it is challenging to know all the true positives and true 
negatives of fusions in real datasets, I used the number of detected fusions from the 
validated fusions to evaluate the sensitivity of deFuse, TophatFusion and QueryFuse. For 
all the candidate fusion events, deFuse and QueryFuse detected the same number of 
events (42 out of 68), while TophatFuion got 37. 
Section 5.2.3: Application to Our Internal Lymphoma Dataset 
Because of partial copy number gain on PD-L2 in the sample TL-03, we 
hypothesized that PD-L2 was involved in a fusion event. Because the expression of PD-
L2 was significantly up-regulated in this sample, we hypothesized that the regulation 
elements were replaced by the fusion gene partner (Section 4.3.2). Using QueryFuse to 
query on PD-L2, I found the hypothesized fusion with three RNA isoforms in this sample 
(Table 5.1) (Bjoern et al. n.d.). All the isoforms supported the same DNA fusion event, in 
which upstream regulation elements of PD-L2 were replaced by elements from 
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TBL1XR1. Additionally, I ran two global fusion-detection algorithms (TophatFusion 
(Kim & Salzberg 2011) and defuse (McPherson et al. 2011)) to validate this finding and 
compared it with QueryFuse. deFuse found two out of three isoforms of this fusion, while 
TophatFusion totally missed this fusion (Table 5.1). This fusion was experimentally 
validated by 5’RACE PCR (Bjoern et al. n.d.). The PCR result showed the isoform found 
by QueryFuse but not deFuse (bold in Table 5.1).  
Gene 
(Partner) 
Breakpoint 
(Partner) 
Gene 
(Query) 
Breakpo
int 
(Query) 
Supportin
g Read # 
(QF) 
deFuse 
Result 
Tophat-
Fusion 
Result 
Read 
# 
PREF 
TBL1XR1 176914910 PD-L2 5522532 63 Yes No 160 
TBL1XR1 176878661 PD-L2 5522531 23 No No 78 
TBL1XR1 176914128 PD-L2 5522533 16 Yes No 32 
Table 5.1: TBL1XR1 - PD-L2 fusion isoforms detected by QueryFuse. The result of three isoforms is 
compared with deFuse, TophatFusion and PREF. The second isoform (bold) is detected by QueryFuse, in 
silico validated by PREF and the only isoform experimentally validated by 5’RACE, but it is not detected 
by either deFuse or TophatFusion.  
From the WES data, I detected seven fusions which were in in-frame regions of 
genes (Bjoern et al. n.d.). As a result, I used deFuse, TophatFusion and QueryFuse on 
matched RNA-Seq data to check the presence of these fusions (Table 5.2). QueryFuse 
and deFuse detected the same number of events from these fusion events, while 
TophatFusion detected none.   
Sample ID # Fusions from WES QueryFuse deFuse TophatFusion 
P_05 1 1 1 0 
TL_03 3 3 3 0 
TL_05 1 1 1 0 
TL_07 1 0 0 0 
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TL_08 1 0 0 0 
Table 5.2: Fusion detection results from matched RNA data on in-frame fusions from WES data.  
 
Section 5.2.4: Discussion 
QueryFuse is sensitive in both simulation datasets and real datasets. 
Overall, among three methods, whether in simulation datasets or in real datasets, 
QueryFuse had the highest number of detecting TPs. In the simulation dataset from 
SimFuse, QueryFuse had the best recall and precision rates for all combinations of 
supporting reads. In the external simulation dataset from FusionMap, QueryFuse had the 
best recall and precision rates as well. In cell line datasets, although the differences in 
performance among the three methods were not as significant as they were in the 
simulation dataset from SimFuse because fusion events in real data generally had 
numerous supporting reads, QueryFuse was still one of the best. Furthermore, in the 
lymphoma patient dataset, only QueryFuse could detect an extra RNA isoform from the 
fusion event, which was experimentally validated. This showed that QueryFuse was 
potentially more sensitive in detecting RNA fusion isoforms than global detection 
methods. However, this hypothesis is hard to validate and further study is necessary. 
QueryFuse fits best for studies with fusion hypothesis on a list of genes. 
QueryFuse is a novel algorithm focusing on gene-specific fusion detection from 
RNA-Seq data. Its strength is to test fusion hypothesis on a list of genes reliably and 
efficiently. With aligned RNA-Seq data, users can check their fusion hypotheses even 
before spending time on experimental validations. By integrating copy number changes 
with gene expression changes, biologists can raise the fusion hypothesis of genes (Bjoern 
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et al. n.d.). Or with DNA-Seq and matched RNA-Seq data, researchers would like to 
check whether a fusion detected in DNA-Seq is expressed in RNA-Seq (Bjoern et al. 
n.d.). In these cases, doing gene-specific fusion detection is more appropriate than doing 
global fusion-detecting, and QueryFuse is designed to meet this need. Additionally, it is 
inefficient for biologists to go through a long list of fusions from a global fusion-
detection tool, because most of the fusions are not related to the genes of interest. Using 
QueryFuse, researchers can focus only on genes of interest. Furthermore, by using the 
ranked results, users can prioritize their focus on the most reliable fusions. 
QueryFuse is fast if the query gene list is less than 16 genes. 
In the 52 million paired-end reads example, running in a single processor, 
QueryFuse took 215 min (80 min preprocessing time + 135 min querying time) to run for 
one query, while deFuse took 1398 min and TophatFusion took 3075 min for a genome-
wide detection. This showed the computational advantage of using the QF algorithm. It is 
true that, in practice, running at parallel mode can save time for deFuse and TophatFusion. 
For example, running in 16 processors, the same sample took 150 min for deFuse and 
516 min for TophatFusion. QueryFuse cannot run parallel for a single query. However, 
for X queries, QueryFuse can run in <=X processors with a one-time preprocessing run at 
the beginning. For a test with 16 random queries in this example in 16 processors, 
QueryFuse took 170 min (80 min preprocessing time + 90 (±102) min querying time). As 
a result, with the same computational resource, for a list of 16 query genes, QueryFuse 
took similar time as deFuse took using 16 cores. Additionally, because the querying time 
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is almost linearly related to the length of the query gene (Appendix Figure 3), QueryFuse 
performs efficiently on short query genes. 
QueryFuse has great clinical potential. 
In the lymphoma study, QueryFuse successfully detected a clinical actionable 
target – a fusion of PD-L2. This can lead to a personalized immunotherapy on this 
specific patient. Given that QueryFuse is optimal for fusion detection on selected genes in 
a given sample, it has great potential application in detecting targets for personalized 
medicine. It can also be used as an efficient tool for fusion detection in targeted 
sequencing panels. 
 
Section 5.3: PREF 
In this section, PREF is first validated by a simulation data from SimFuse. Then 
PREF is used in the lymphoma study (Section 4.3.2) to validate the TBL1XR1 – PD-L2 
fusion.  
Section 5.3.1: Performance Estimation Using Simulated Data 
For PREF, I estimated its sensitivity and specificity separately.  
To estimate PREF’s sensitivity, I used simulation data, which has 9 supporting 
read groups (Split:Span: 1:1, 1:5, 1:10, 5:1,5:5, 5:10, 10:1, 10:5 and 10:10) and 1600 
fusions in each group. In each group, simulated fusions are used as putative references in 
PREF. From the result (Appendix Table 7), PREF is proved to be >98% sensitive to find 
splitting reads but poor (<60% in maximum) on detecting spanning reads.  
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To estimate PREF’s specificity, I used fusion-free RNA-Seq datasets with known 
expression profile as the input. Exons in this dataset were grouped by raw counts of reads 
([0,100], (100,101], (101,102], (102,103], (103,104], (104,105] and >105). Putative references 
were randomly generated by merging exons by combinations of raw counts groups. For 
example, group 0:0 means the two partners of a fusion are both from the raw counts 
group of [0,100], while group 5:1 means the first partner of a fusion is from the raw 
counts group of (104,105], and the second partner is from the raw counts group of 
(100,101]. There are 49 (72) groups in all, and each group has 2000 random putative 
references. From the results (Appendix Table 8), PREF is shown to have >99.3% 
specificity when one splitting read is used as the cutoff and >99.8 specificity when the 
cutoff is ten splitting reads.  
Section 5.3.2: Application to Our Internal Lymphoma Dataset 
PREF was applied to our patient primary lymphoma dataset (Section 4.3.2) to 
validate the three isoforms detected by QueryFuse (Section 5.2.3). Table 5.1 shows that 
PREF was able to detect all three isoforms with more than twice the supporting reads 
compared with QueryFuse. This shows that PREF is not only a reliable fusion validation 
tool, but also a useful tool to extract the full set of fusion supporting reads from RNA-Seq 
data.  
Section 5.3.3: Discussion 
PREF is effective in detecting splitting reads of a fusion, but improvement is 
needed on detecting spanning reads. Therefore, PREF uses only the number of splitting 
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reads (default is 10, but for data with low depth, it can be smaller) as cutoff at this stage. 
However, this won’t affect PREF’s value in application because the state-of-the-art 
library preparation of RNA-Seq data generates nearly no spanning reads. Although using 
only the splitting read number as cutoff is a weak criteria, PREF reaches excellent 
specificity (>99.8%), which makes PREF a reliable validation tool for fusions. Also, the 
main cause of the false discovers is the homologous regions in the genome, which results 
in ambiguous alignments. 
The patient primary lymphoma study showed a good example of PREF’s 
application in real data to validate detected fusion from RNA-Seq data. It can extract 
much more deeply for supporting reads (especially splitting reads) than QueryFuse. 
deFuse and TophatFusion also reported the supporting read numbers, but no supporting 
evidence (such as readID) was provided to confirm that they are exactly the read count 
without double counting. As a result, I could not use their numbers to compare with 
PREF.  
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CHAPTER 6: CONCLUSIONS 
The results presented in this dissertation provide support for the following 
conclusions: 
 The RNA-Seq data processing pipeline (Hydra) is fast and reliable to facilitate users’ 
data analysis tasks by saving time and labor. It is sensitive enough to detect poor 
quality samples or samples with contaminations. 
 QueryFuse is a novel gene-specific fusion-detection tool using RNA-Seq data, and 
meets the need of biologists for fusion hypothesis testing. QueryFuse has comparable 
or better fusion detection performance on simulation datasets, cell line datasets and 
patient datasets, compared with two state-of-the-art fusion detectors (defuse 
(McPherson et al. 2011) and TophatFusion (Kim & Salzberg 2011)). Algorithm-wide, 
QueryFuse is much more efficient than the other two tools, although, in practice, the 
run time with parallelization is not much shorter, mainly because of QueryFuse’s 
poor implementation of parallelization.  
 SimFuse is a unique RNA-Seq based fusion simulator that provides control on 
supporting read numbers and types in a considerable sample size to gain statistical 
power. Using simulation data from SimFuse, users can estimate supporting read-
specific performance, which is impossible with other existing simulation data or 
tools. 
 PREF is reliable as an in silico fusion validation tool with high sensitivity and 
specificity.  
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Section 6.1: Contributions 
Section 6.1.1: RNA-Seq Data Processing Pipeline 
 I proposed and built the original prototype of the RNA-Seq data processing pipeline 
with portable modules and informative reports. 
 I applied the pipeline in multiple research projects and proved its reliability and 
ability to save time and labor. 
 By using the pipeline on PDX data (Section 5.3.2), I showed that it is useful and 
efficient to help users find low-quality samples and samples with contamination. 
Section 6.1.2: RNA-Seq Based Fusion Detection 
 I proposed a new algorithm of fusion detection by using additional information from 
paired ends. This algorithm has great potential to speed up fusion detection analysis 
with high accuracy. It has a unique advantage in doing gene-specific fusion detection 
by quickly narrowing down the targets. 
 I developed QueryFuse, a novel gene-specific fusion detector as a proof of concept of 
the new algorithm. Compared with two state-of-the-art RNA-Seq based fusion 
detectors, defuse (McPherson et al. 2011) and TophatFusion (Kim & Salzberg 2011), 
QueryFuse is proved to have better performance on recall, precision and speed. 
Careful performance estimation was executed with both simulation data and cell line 
data with known fusions. A unique and notable property of QueryFuse is gene-
specific, which meet biologists’ needs for fusion hypothesis testing and targeted 
research on only a list of genes. In the lymphoma study (Section 5.2.3), I successfully 
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proved this property of QueryFuse and got a clinically meaningful fusion, which 
matches the biological hypothesis. Furthermore, QueryFuse provides details of 
supporting information of detected fusion, such as read ID and piled-up graph of 
supporting reads (Appendix Figure 4), which is not available in most existing fusion-
detection tools. 
 I developed a novel fusion simulator from RNA-Seq data, which can automatically 
generate a customizable and statistically powerful fusion dataset from RNA-Seq. 
Compared with existing RNA-Seq based fusion simulation datasets, SimFuse makes 
it much easier and with higher resolution (supporting read-specific level) to 
systematically evaluate the performance of RNA-Seq based fusion-detection 
algorithms.  
 I introduced PREF, a novel in silico fusion validation method. PREF is tested on 
simulation data and proved to be valuable for evaluating fusions computationally, 
which can narrow down the targets for downstream experimental validation.  
Section 6.2: Future Work 
Section 6.2.1: RNA-Seq Based Data Processing Pipeline 
 Although Hydra is tested to be portable, platform independent and parallel, further 
testing on more computational environments with bigger data size is necessary. 
 Hydra is modulated for each step, and more modules for new state-of-the-art methods 
are still under development to meet various needs from users.   
 Currently, Hydra streamlines the process only to quantification analysis. Standardized 
downstream analysis, such as fusion detection, should be included in the future.  
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Section 6.2.2: QueryFuse 
 QueryFuse, as a gene-specific algorithm that makes use of the known query gene to 
narrow down fusion targets, should be more efficient than existing seed methods 
because it is more targeted and uses more information, which was validated in a 
comparison using a single core. Additionally, I showed that QueryFuse was faster 
than other global fusion detection methods even in parallel mode, when the query 
gene list was less than 16 genes. However, QueryFuse’s implementation is not 
computationally efficient enough on parallelization and there is room for 
improvement.  
 Meanwhile, the sensitivity and specificity of blat (the local aligner I am using) drop 
significantly when the reads are short (less than 30 bp). As a result, replacing blat 
with a better local aligner should improve QueryFuse’s performance (recall and 
precision), which requires further testing. 
 At this time, QueryFuse’s input must be the aligned BAM file from RNA-Seq 
aligners without fusion detection features, such as Tophat, SOAP, etc. However, it is 
noted that some new aligners, such as STAR, have integrated fusion detection as the 
default in the regular read alignment step. Because fusion supporting reads from these 
integrated aligners are annotated differently, complementary options for using the 
output from these new aligners will be included in QueryFuse in the future. 
 With the development of sequencing technology, long single-end sequencing might 
become popular. Although QueryFuse can work only on paired-end sequencing data 
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now, it should theoretically work for single-end sequencing as well, which will 
require additional improvements. 
Section 6.2.3: SimFuse 
 SimFuse already allows for the control of fusion parameters (such as number of 
supporting reads and ratio of splitting-to-spanning reads) and relies on a reference 
genome template for the generation of the fusion supporting reads, but additional 
parameters will be included in future improvements to more closely approximate real 
data. For example, I can introduce tunable mutation rates for each base in the 
template genome reference, or relax the location requirement of fusion boundaries, or 
offer the option of alternative splicing conjunction between exons.  
 SimFuse is available as open source software on github, and input from any 
developers is welcome. Our hope is that this package will provide for a starting point, 
and that additional functions and improvements will be contributed by the community. 
Section 6.2.4: PREF 
 PREF provides a proof of concept of doing in silico fusion validation. However, it is 
not software engineered well. The runtime performance has a great deal to improve. It 
is using Bowtie2 as the sequence alignment module now, and it may be beneficial to 
replace it with a more customized aligner to improve sensitivity, specificity and speed 
in the future. 
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 PREF is not sensitive enough on detecting spanning reads. Theoretically, this should 
not happen. Therefore, further investments on the cause and potential solutions are 
necessary.  
 PREF is platform dependent and not well tested in different running environments yet. 
Future programming works include packaging, portability testing and parallelization. 
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APPENDIX TABLES 
Split:Span 
read # per 
fusion 
1:0 3:1 5:1 7:2 10:3 15:4 20:5 30:8 50:13 
100: 
26 
Simulation1 100  100  100  100  100  100  100  100  100  100  
Simulation2 100  100  100  100  100  100  100  100  100  100  
…… …… …… …… …… …… …… …… …… …… …… 
Simulation 
100 
100  100  100  100  100  100  100  100  100  100  
Appendix Table 1: Simulation matrix used to generate the SimFuse example dataset. In each cell, 
there are 100 fusions simulated. 
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Appendix Table 2: Fusion detection results on breast cancer cell lines. Red marks the fusions supported 
by only spanning reads. Blue marks fusions missed by all three fusion-detection algorithms. 
 
Method deFuse TophatFusion QueryFuse 
Split 
# 
Span 
# 
recall STD 95% 
CI 
recall STD 95%
CI 
recall STD 95%
CI 
1 0 0 0 0 0 0 0 0 0 0 
3 1 0 0 0 0.755 0.042 0.008 0.762 0.038 0.008 
5 1 0 0.001 0 0.795 0.035 0.007 0.856 0.039 0.008 
7 2 0.009 0.009 0.002 0.813 0.038 0.007 0.885 0.031 0.006 
10 3 0.089 0.034 0.007 0.822 0.031 0.006 0.885 0.035 0.007 
15 4 0.339 0.051 0.010 0.833 0.036 0.007 0.887 0.070 0.014 
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20 5 0.745 0.069 0.014 0.839 0.039 0.008 0.899 0.031 0.006 
30 8 0.787 0.066 0.013 0.837 0.036 0.007 0.903 0.034 0.007 
50 13 0.821 0.059 0.012 0.845 0.036 0.007 0.880 0.035 0.007 
100 26 0.843 0.060 0.012 0.840 0.033 0.006 0.885 0.036 0.007 
Appendix Table 3: Recall statistics among QueryFuse, deFuse and TophatFusion. For each method, 
standard deviation (STD) and 95% confidential interval (CI) were calculated from 100 repeat runs.  
 
Method deFuse TophatFusion QueryFuse 
Split  Span  Prec. STD 95%
CI 
Prec. STD 95%
CI 
Prec. STD 95%
CI 
1 0 0 0 0 NA NA NA NA NA NA 
3 1 0 0 0 0.986 0.014 0.003 0.989 0.012 0.002 
5 1 0.026 0.147 0.038 0.985 0.014 0.003 0.985 0.014 0.003 
7 2 0.502 0.404 0.086 0.984 0.013 0.002 0.986 0.016 0.003 
10 3 0.871 0.112 0.022 0.980 0.014 0.003 0.987 0.012 0.002 
15 4 0.931 0.043 0.008 0.979 0.015 0.003 0.993 0.010 0.002 
20 5 0.945 0.027 0.005 0.978 0.014 0.003 0.993 0.010 0.002 
30 8 0.947 0.025 0.005 0.979 0.016 0.003 0.993 0.010 0.002 
50 13 0.951 0.022 0.004 0.977 0.014 0.003 0.994 0.010 0.002 
100 26 0.948 0.029 0.006 0.979 0.017 0.003 0.992 0.010 0.002 
Appendix Table 4: Precision statistics among QueryFuse, deFuse and TophatFusion. For each method, 
standard deviation (STD) and 95% confidential interval (CI) were calculated from 100 repeat runs. 
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Sample 
ID 
Read 
Length 
Mean 
Fragment 
Length 
Validated 
Fusion 
Events 
deFuse 
Tophat-
Fusion 
Query-
Fuse 
H2228_A
5M_R1 
99 177 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
H2228_A
5M_R2 
99 177 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
PTPN3 
H2228_A
5M_R3 
99 177 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
H2228_A
5M_48hr 
99 177 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
ALK-
EML4, 
ALK-
PTPN3 
H2228_A
5M_72hr 
99 177 
ALK-
EML4, 
ALK-
EML4, 
ALK-
EML4, 
ALK-
EML4, 
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ALK-
PTPN3 
ALK-
PTPN3 
ALK-
PTPN3 
ALK-
PTPN3 
DHL_R1 99 177 
ALK-
NPM1 
ALK-
NPM1 
None 
ALK-
NPM1 
DHL_R2 99 177 
ALK-
NPM1 
ALK-
NPM1 
ALK-
NPM1 
ALK-
NPM1 
DHL_R3 99 177 
ALK-
NPM1 
ALK-
NPM1 
None 
ALK-
NPM1 
Appendix Table 5: Fusion detection results on ALK dataset. 
 
Sampl
e ID 
Read 
Length 
Mean 
Fragment 
Length 
Validated 
Fusion Events 
deFuse 
Tophat-
Fusion 
QueryFuse 
SRR4
97884 
90 189 
BDKRB2-
BDKRB1, 
CIRH1A-
TMCO7, 
CLN6-
CALML4, 
GATSL1-
GTF2I, 
HADHB-
CIRH1A-
TMCO7, 
HADHB-
RBKS, 
TIAM1-
ATP5O 
CIRH1A-
TMCO7, 
HADHB-
RBKS, 
TIAM1-
ATP5O 
CIRH1A-
TMCO7, 
HADHB-
RBKS, 
TIAM1-
ATP5O 
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RBKS, 
POLA2-
CDC42EP2, 
PSMD8-
SIPA1L3, 
TIAM1-
ATP5O 
SRR4
97885 
90 189 
BDKRB2-
BDKRB1, 
CIRH1A-
TMCO7, 
CLN6-
CALML4, 
CTBS-GNG5, 
HADHB-
RBKS, 
PSMD8-
SIPA1L3, 
TIAM1-
ATP5O 
CIRH1A-
TMCO7, 
PSMD8-
SIPA1L3, 
TIAM1-
ATP5O 
CIRH1A-
TMCO7, 
HADHB-
RBKS, 
TIAM1-
ATP5O 
CIRH1A-
TMCO7, 
HADHB-
RBKS, 
TIAM1-
ATP5O 
Appendix Table 6: Fusion detection results on bladder cancer cell lines. 
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 Split Number Cutoff Span Number Cutoff 
Split:Span 
Read # Per Fusion 
1 5 10 1 5 10 
1:1 1 0 0 0.109 0 0 
1:5 1 0 0 0.381 0.011 0 
1:10 1 0 0 0.582 0.079 0.006 
5:1 1 0.994 0 0.101 0 0 
5:5 1 0.995 0 0.379 0.013 0 
5:10 1 0.997 0 0.512 0.071 0.004 
10:1 1 1 0.988 0.092 0 0 
10:5 1 1 0.993 0.343 0.014 0 
10:10 1 1 0.991 0.466 0.084 0.006 
Appendix Table 7: Sensitivity of PREF on validating simulated fusions. Cutoffs of 1, 5 and10 
supporting reads are used on either splitting read counts or spanning read counts. Sensitivity equals to the 
number of fusions validated by PREF and fulfills the cutoff requirement, divided by 1600 (the number of 
fusions simulated in each bin). N:M group means all the fusions in this group have N splitting reads and M 
spanning reads. 
 
Calling cutoff: 1 splitting read 
Read 
Count Groups 
0 1 2 3 4 5 >5 
0 1 0.999 0.999 0.999 0.998 0.993 0.999 
1 1 1 0.999 0.999 0.997 0.996 0.998 
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2 1 0.999 1 1 0.998 0.997 0.999 
3 1 1 1 0.999 0.999 0.993 0.998 
4 0.999 1 1 0.999 0.003 0.996 0.999 
5 1 1 1 0.999 0.998 0.995 0.999 
>5 1 0.999 1 1 0.998 0.995 0.995 
Calling cutoff: 10 splitting read 
Read 
Count Groups 
0 1 2 3 4 5 >5 
0 1 1 1 1 1 0.999 0 
1 1 1 1 1 1 1 0.999 
2 1 1 1 1 1 1 1 
3 1 1 1 1 1 0.998 1 
4 1 1 1 1 0.999 1 1 
5 1 1 1 1 1 1 1 
>5 1 1 1 1 1 0.999 0.998 
Appendix Table 8: Specificity estimation of PREF using a fusion-free background. Two cutoffs were 
applied: 1 and10 splitting reads for PREF to call a fusion validated. The horizontal group numbers stand for 
the expression group in which the partner1 in each fusion is from. The vertical group numbers stand for the 
expression group in which the partner2 in each fusion is from. Specificity equals to 1 – (number of random 
putative references validated by PREF and fulfill the cutoff requirement ÷ 2000 (the number of random 
putative references used in each bin)).  
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APPENDIX FIGURES 
 
Appendix Figure 1: Dispersion of splitting reads. a) Dashed line is the fusion breakpoint. On the left, all 
the supporting reads are piled up at the same location, which is the evidence of PCR artifacts and makes the 
fusion less reliable. On the right, all the supporting reads are well spread, which indicates no PCR artifacts. 
b) Theoretical distribution of coverages on each base, which should be a normal distribution. 
 
 
Appendix Figure 2: FastQC per base sequence quality score plot of a PDX sample. The central read 
line is the median value. The yellow box represents the inter-quartile range (2575%). The upper and lower 
whiskers represent the 10% and 90% points. The blue line represents the mean quality. The y-axis is the 
quality score. The x-axis is the base location of a read.  
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Appendix Figure 3: Plot of QueryFuse’s runtimes on genes with different lengths. The x-axis is gene 
lengths (base pairs). The y-axis is runtimes. The 16 genes used were randomly drawn from the genome 
(blue diamonds). The black line shows the linear relation between gene lengths and runtimes.  
 
 
Appendix Figure 4: Piled up plot a TBL1XR1 – PD-L2 isoform detected by QueryFuse. The top left 
corner is the table of fusion information, including gene ID, putative reference’s 5’ and 3’ location and the 
fusion boundaries. In the graph, the left side lists read ID information and the right side lists read sequences. 
The first line is the putative reference generated from the detected fusion. Red represents the sequences 
from the 5’ fusion partner, while blue represents sequences from the 3’ fusion partner.  
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APPENDIX FILE 
######################################################################## 
# Standard parameters 
######################################################################## 
#working directory where a results and report directory will be created 
working_dir     =    /restricted/projectnb/montilab-
p/projects/superfund/project5/RNASeq2/ 
 
#file that contains 2 or 3 columns with fastq | [fastq2]  | stub 
raw_filenames   =    /restricted/projectnb/montilab-
p/CBMrepository/users/gusef/RNASeq_pipeline/filenames_example.txt 
 
#Does the raw_filenames file have a header? 
raw_file_header =    TRUE 
 
#paired end reads? 
paired         =    FALSE 
 
#start pipeline from scratch or try to pick up at the last step that was performed 
successfully 
clean_run       =    FALSE 
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#directory that contains all the python scripts 
scripts_dir     =   /restricted/projectnb/montilab-
p/CBMrepository/users/gusef/RNASeq_pipeline/ 
 
#should everything also be printed on the command line 
verbose         =    TRUE 
 
#chose the aligner 
aligner = tophat     #right now only 'skip' and 'tophat' are allowed 
 
 
######################################################################## 
# QSUB parameters 
######################################################################## 
run_single_cpu = FALSE         #in case you have nothing to do for the next 2 month or so 
give this option a try!! 
 
modules_python2.6 = FASTX-Toolkit/fastx_toolkit-0.0.13.2_gnu446_x86_64, 
boost/boost_1_51_0_gnu446, samtools/samtools-0.1.19_gnu446, bowtie2/bowtie2-2.0.0-
beta7_gnu446, tophat/tophat-2.0.6_gnu446, cufflinks/cufflinks-2.0.2_gnu446 
modules_python2.7 = python2.7/Python-2.7.3_gnu446, pysam/pysam_0.7.7_gnu446 
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qsub_email          = gusef@bu.edu 
qsub_send_email     = FALSE 
qsub_memory         = 2g 
qsub_suffix         = pbs 
qsub_PROJECT        = montilab-p 
qsub_MACHINE        = scc 
qsub_RUNTIME_LIMIT  = 96:00:00     
qsub_wait_time      = 10 
qsub_num_processors = 4-8 
 
 
######################################################################## 
# TRIMMING 
######################################################################## 
do_trimming      =     FALSE 
trimming_exec    =     fastx_trimmer    #on SCC we don't need to specify the location of 
the executable we just need to load the proper module 
trimming_mode    =     -l    # can be -l (last base to keep), -f (first base to keep), or -t (trim 
N nucleotides at the end) 
trimming_value   =     45    # value that goes with the mode 
trimming_quality_value    =     -Q33  # optional: Q33 works for sanger 
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######################################################################## 
#FAST QC 
######################################################################## 
fastqc_exec      =       /restricted/projectnb/montilab-p/tools/FastQC_v0.10.1/fastqc    
 
######################################################################## 
#TOPHAT 
######################################################################## 
tophat_exec                 =   tophat2     #on SCC we don't need to specify the location of the 
executable we just need to load the proper module 
tophat_index                =   /restricted/projectnb/montilab-
p/CBMrepositoryData/annot/zebrafish/Danio_rerio.Zv9 
tophat_qual                 =   none        #  can be none, --solexa-quals or --solexa1.3-quals 
tophat_N                    =   2           #--read-mismatches  
tophat_gap_length           =   2 
tophat_edit_dist            =   2 
 
######################################################################## 
#BAMQC 
######################################################################## 
bamqc_exec                  =  python2.7 
bamqc_script                =  run_bamqc.py 
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######################################################################## 
#CUFFLINKS 
######################################################################## 
cufflinks_exec           = cufflinks     #on SCC we don't need to specify the location of the 
executable we just need to load the proper module 
cufflinks_G              = /restricted/projectnb/montilab-
p/CBMrepositoryData/annot/zebrafish/Danio_rerio.Zv9.75.gtf  # -G/--GTF 
<reference_annotation.(gtf/gff)> 
cufflinks_b              = /restricted/projectnb/montilab-
p/CBMrepositoryData/annot/zebrafish/Danio_rerio.Zv9.75.fa             #-b/--frag-bias-
correct <genome.fa> 
cufflinks_compatible_hits = inactive           #Cufflinks counts only those fragments 
compatible with some reference transcript towards the number of mapped hits used in the 
FPKM denominator. (can be 'active' to turn it on)  
cufflinks_library_type   = fr-unstranded 
 
#The following parameter all normalize the counts during the cufflinks run. However, if 
you intend to run edgeR afterwards you need raw counts not fpkm  
cufflinks_total_hits     = active           #create FPKM (can be 'active' for turning this 
option on or anything else to turn it off) 
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cufflinks_N              = active           #upper quantile normalization (can be 'active' for 
turning this option on or anything else to turn it off) 
cufflinks_u              = active           #multi read correct (can be 'active' for turning this 
option on or anything else to turn it off) 
 
 
######################################################################## 
#HT-Seq 
######################################################################## 
HTSeq_exec    =  htseq-count 
sam_exec      =  samtools 
HTSeq_s       =  no           #stranded? (yes/no/reverse) 
HTSeq_t       =  exon         #feature type  
HTSeq_m       =  union        #union, intersection-strict and intersection-nonempty 
HTSeq_gft     =  /restricted/projectnb/montilab-
p/CBMrepositoryData/annot/zebrafish/Danio_rerio.Zv9.75.gtf 
Rscript_exec  =  Rscript 
########################################### 
Appendix File 1: A parameter file example for Hydra. The contents behind “#” are 
comments.  Names in front of “=” are parameter names and the parts after “=” are 
parameter values. 
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